Fresenius Medical Care AG & Co. KGaA (FMS) 6-K 6 May 14 2014 Q1 Current report (foreign) Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Document and Entity Information [Abstract]	'
Document period end date	31-Mar-14
Amendment flag	'false
Entity registrant name	'FRESENIUS MEDICAL CARE AG & Co. KGaA
Entity current reporting status	'Yes
Entity voluntary filers	'Yes
Entity central index key	'0001333141
Document type	'6-K
Current fiscal year end date	'--12-31
Entity filer category	'Large Accelerated Filer
Entity well known seasoned issuer	'Yes
Entity common stock shares outstanding	301,491,046
Entity public float	$17,790,161,435
Document Fiscal Year Focus	'2014
Document Fiscal Period Focus	'Q1

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net revenue:	'	'
Dialysis Care Revenue	$2,845,424	$2,741,935
Valuation Allowances and Reserves, Adjustments	-63,237	-63,749
Net Dialysis care revenue	2,782,187	2,678,186
Dialysis Products Revenue	781,405	785,735
Net revenue	3,563,592	3,463,921
Costs of revenue:	'	'
Dialysis Care Cost of Revenue	2,117,604	1,984,224
Dialysis Products Cost of Revenue	363,856	370,179
Cost of revenues	2,481,460	2,354,403
Gross profit	1,082,132	1,109,518
Operating expenses:	'	'
Selling, general and administrative	619,733	591,714
Research and development	30,028	30,372
Income from equity method investees	-12,522	-4,808
Gain on the sale of dialysis clinics	-2	-1,073
Operating income	444,895	493,313
Other (income) expense:	'	'
Interest income	-15,415	-10,589
Interest expense	111,676	114,818
Income before income taxes	348,634	389,084
Income tax expense	101,284	129,001
Net Income	247,350	260,083
Less: Net income attributable to noncontrolling interests	41,888	34,584
Net Income attributable to the Company	$205,462	$225,499
Basic income per Ordinary share	$0.68	$0.74
Earning Per Share Diluted	$0.68	$0.73

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Consolidated Statements of Comprehensive Income	'	'
Net Income	$247,350	$260,083
Other comprehensive income loss derivatives qualifying as hedges before tax	6,959	15,897
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,354	6,398
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-47,056	-68,192
Other comprehensive income loss tax	-3,550	-6,684
Other comprehensive income (loss), net of tax	-39,293	-52,581
Total comprehensive income	208,057	207,502
Comprehensive income attributable to Noncontrolling interests	41,855	32,602
Comprehensive income attributable to the Company	$166,202	$174,900

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$574,127	$682,777
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	3,080,334	3,037,274
Accounts receivable from related parties	171,186	153,118
Inventories	1,206,772	1,097,104
Prepaid expenses and other current assets	1,195,392	1,037,391
Deferred tax asset, current	268,910	279,052
Total current assets	6,496,721	6,286,716
Property, plant and equipment, net	3,135,123	3,091,954
Intangible assets	734,227	757,876
Goodwill	11,646,157	11,658,187
Deferred tax asset, non-current	108,480	104,167
Equity Method Investments	733,912	664,446
Other assets	568,057	556,560
Total assets	23,422,677	23,119,906
Current liabilities:	'	'
Accounts payable	550,668	542,597
Accounts payable to related parties	164,229	123,929
Accrued expenses and other current liabilities	1,900,239	2,012,533
Short-term borrowings and other financial liabilities	157,226	96,648
Short-term borrowings from related parties	134,314	62,342
Current portion of long-term debt and capital lease obligations	301,275	511,370
Income tax payable, current	203,554	170,360
Deferred tax liability, current	35,811	34,194
Total current liabilities	3,447,316	3,553,973
Total long-term debt less current maturities	8,016,155	7,746,920
Other liabilities	333,220	329,561
Pension liabilities	413,388	435,858
Income tax payable, non-current	166,040	176,933
Deferred tax liability, non-current	734,329	743,390
Total liabilities	13,110,448	12,986,635
Noncontrolling interests subject to put provisions	631,940	648,251
Company shareholders' equity:	'	'
Common stock, no par value, 1.00 Euro nominal value, 392,462,972 shares authorized, 309,111,125 issued and 301,562,174 outstanding	382,569	382,411
Treasury Stock	505,014	505,014
Additional paid-in capital	3,553,425	3,530,337
Retained earnings	6,582,879	6,377,417
Accumulated other comprehensive (loss)	-589,847	-550,587
Total Company shareholders' equity	9,424,012	9,234,564
Minority interest	256,277	250,456
Total equity	9,680,289	9,485,020
Total liabilities and equity	$23,422,677	$23,119,906

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals)	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)
Consolidated Balance Sheets	'	'	'
Trade accounts receivable allowance for doubtful accounts	$403,657	'	$413,165
Preference shares, no par value (in Euros)	'	€ 1	'
Common stock no par value (in Euros)	'	€ 1	'
Common stock authorized	392,462,972	392,462,972	'
Common stock issued	308,995,730	308,995,730	'
Common stock outstanding	301,446,779	301,446,779	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating Activities:	'	'
Net Income	$247,350	$260,083
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	167,167	156,353
Change in deferred taxes, net	-3,459	-22,455
(Gain) loss on sale of investments	-2	-1,073
(Gain) loss on sale of fixed assets	808	1,401
Stock Option Compensation Expense	6,174	6,220
Dividend income from equity method investees	32,399	18,582
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	-62,915	-40,702
Inventories, net	-111,648	-56,173
Prepaid expenses, other current and non-current assets	-26,831	32,079
Accounts receivable, related parties	-18,215	-24,934
Accounts payable, related parties	41,018	23,459
Accounts payable, accrued expenses and other current and non-current liabilities	-180,308	-99,671
Income tax payable	20,756	62,249
Net cash provided by (used in) operating activities	112,294	315,418
Investing Activities:	'	'
Purchases of property, plant and equipment	-199,631	-147,357
Proceeds from sale of property, plant and equipment	2,480	1,327
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	-137,157	-72,214
Proceeds from divestitures	2,381	1,036
Net cash (used in) provided by investing activities	-331,927	-217,208
Financing Activities:	'	'
Proceeds from short-term borrowings and other financial liabilities	40,200	46,349
Repayments of short-term borrowings and other financial liabilities	-35,277	-41,930
Proceeds from short-term borrowings from related parties	72,178	4,226
Repayments of short-term borrowings from related parties	'	-1,606
Proceeds from long-term debt and capital lease obligations (net of debt issuance costs and other hedging costs of $156,391 in 2012)	271,544	598
Repayments of long-term debt and capital lease obligations	-267,486	-32,915
Increase (decrease) of accounts receivable securitization program	68,000	-162,000
Proceeds from exercise of stock options	5,807	4,635
Proceeds from conversion of preference shares into ordinary shares	-52,157	'
Distributions to Noncontrolling interests	'	-72,619
Contributions from noncontrolling interests	13,402	8,795
Cash provided by (used in) financing activities	116,211	-246,467
Effect of exchange rate changes on cash and cash equivalents	-5,228	-4,942
Cash and Cash Equivalents:	'	'
Net (decrease) in cash and cash equivalents	-108,650	-153,199
Cash and cash equivalents at beginning of period	682,777	688,040
Cash and cash equivalents at end of period	$574,127	'

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Preferred Stock, No par value [Member]	Common Stock, No par value [Member]	Treasury Stock Equity	Additional paid in capital [Member]	Retained earnings [Member]	Accumulated other comprehensive income (loss) [Member]	Total FMC-AG and Co. KGaA [Member]	Noncontrolling interests not subject to put provisions [Member]
In Thousands, except Share data, unless otherwise specified
Shareholders equity at Dec. 31, 2012	'	'	$374,915	'	$3,491,581	$5,563,661	($492,113)	$8,942,506	$264,754
Shares issued at Dec. 31, 2012	'	3,973,333	302,739,758	'	'	'	'	'	'
Proceeds from exercise of options and related tax effects	105,554	3	'	'	102,520	'	'	105,554	'
Shares from exercise of options and related tax effects	'	2,200	2,280,439	'	'	'	'	'	'
Proceeds from conversion of preference shares	34,784	-4,465	'	'	34,784	'	'	34,784	'
Preference share conversion	'	-3,975,533	3,975,533	'	'	'	'	'	'
Compensation expense related to stock options	-13,593	'	'	'	-13,593	'	'	-13,593	'
Dividends paid	296,134	'	'	'	'	296,134	'	296,134	'
treasury stock value	-505,014	'	'	-505,014	'	'	'	-505,014	'
treasury stock shares	'	'	'	-7,548,951	'	'	'	'	'
Minority interest increase from stock issuance	-15,173	'	'	'	-3,566	'	'	-3,566	-11,607
Minority interest decrease from distributions to noncontrolling interest holders	-32,275	'	'	'	'	'	'	'	-32,275
Changes in fair value of noncontrolling interests	-108,575	'	'	'	-108,575	'	'	-108,575	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	-61,467	'	'	'	'	'	-58,474	-58,474	-2,993
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	1,142,467	'	'	'	'	1,109,890	'	1,109,890	32,577
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	1,081,000	'	'	'	'	'	'	1,051,416	29,584
Shareholders equity at Dec. 31, 2013	9,485,020	'	'	-505,014	'	6,377,417	-550,587	9,234,564	250,456
Shares issued at Dec. 31, 2013	'	'	'	-7,548,951	'	'	'	'	'
Proceeds from exercise of options and related tax effects	5,801	'	158	'	5,643	'	'	5,801	'
Shares from exercise of options and related tax effects	'	'	115,395	'	'	'	'	'	'
Compensation expense related to stock options	6,174	'	'	'	6,174	'	'	6,174	'
Minority interest increase from stock issuance	-2,879	'	'	'	-2,576	'	'	-2,576	-303
Minority interest decrease from distributions to noncontrolling interest holders	-8,951	'	'	'	'	'	'	'	-8,951
Changes in fair value of noncontrolling interests	13,847	'	'	'	13,847	'	'	13,847	'
Comprehensive income net of tax including portion attributable to noncontrolling interest abstract	'	'	'	'	'	'	'	'	'
Other comprehensive income loss net of tax period increase decrease less amounts attributable to noncontrolling interests subject to put provisions	-39,305	'	'	'	'	'	-39,260	-39,260	-45
Profit loss less amounts attributable to noncontrolling interests subject to put provisions	220,582	'	'	'	'	205,462	'	205,462	15,120
Comprehensive income net of tax including portion attributable to noncontrolling interest less amounts attributable to noncontrolling interests subject to put provisions	181,277	'	'	'	'	'	'	166,202	15,075
Shareholders equity at Mar. 31, 2014	$9,680,289	'	'	($505,014)	$3,553,425	$6,582,879	($589,847)	$9,424,012	$256,277
Shares issued at Mar. 31, 2014	'	'	'	-7,548,951	'	'	'	'	'

The_Company_Basis_of_Presentat

The Company, Basis of Presentation, Healthcare Reform and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
The Company and Basis of Presentation	'
	1. The Company and Basis of Presentation
	The Company
	Fresenius Medical Care AG & Co. KGaA (“FMC-AG & Co. KGaA” or the “Company”), a German partnership limited by shares (Kommanditgesellschaft auf Aktien), is the world's largest kidney dialysis company, operating in both the field of dialysis care and the field of dialysis products for the treatment of end-stage renal disease (“ESRD”). The Company's dialysis care business, in addition to providing dialysis treatments to patients with ESRD, includes pharmacy services, vascular access surgery services and laboratory services (together, “Care Coordination”). The Company's dialysis products business includes manufacturing and distributing products for the treatment of ESRD. The Company's dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a broad range of products. In addition, the Company sells dialysis products to other dialysis service providers. In the United States (“U.S.”), the Company also provides inpatient dialysis services as well as other services under contract to hospitals.
	In these unaudited consolidated financial statements, “FMC-AG & Co. KGaA,” or the “Company,” “we,” “us” or “our” refers to the Company or the Company and its subsidiaries on a consolidated basis, as the context requires. The term “North America Segment” refers to the North America operating segment. The term “International Segment” refers to the combined Europe, Middle East, Africa and Latin America (“EMEALA”) operating segment and the Asia-Pacific operating segment. For further discussion of our operating segments, see Note 13 “Segment and Corporate Information.”
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
	The consolidated financial statements at March 31, 2014 and for the three-months ended March 31, 2014 and 2013 contained in this report are unaudited and should be read in conjunction with the consolidated financial statements contained in the Company's 2013 Annual Report on Form 20-F. The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Such financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of the results of the periods presented. All such adjustments are of a normal recurring nature.
	The accounting policies applied in the accompanying consolidated financial statements are the same as those applied in the consolidated financial statements at and for the year ended December 31, 2013, contained in the Company's 2013 Annual Report on Form 20-F.
	Certain items, in the net aggregate amount of $5,006 relating to research and development, compensation expense, and income from equity method investees have been reclassified in the prior year's comparative consolidated financial statements between the North America Segment, the International Segment and Corporate, as applicable, to conform to the current year's presentation.
	The results of operations for the three-months ended March 31, 2014 are not necessarily indicative of the results of operations for the year ending December 31, 2014.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Related Party Transactions	'
	2. Related Party Transactions
	The Company's parent, Fresenius SE & Co. KGaA (“Fresenius SE”), a German partnership limited by shares, owns 100% of the share capital of Fresenius Medical Care Management AG, the Company's general partner (“General Partner”). Fresenius SE is also the Company's largest shareholder and owns approximately 31.3% of the Company's outstanding shares at March 31, 2014. The Company has entered into certain arrangements for the purchase and sale of products and services with Fresenius SE or its subsidiaries and with certain of the Company's joint ventures as described in items a), b) and d) below. The Company's terms related to the receivables or payables for these products and services are generally consistent with the normal terms of the Company's business. Financing arrangements as described in item c) below normally have agreed upon terms which are determined at the time such financing transactions occur and usually reflect market rates at the time of the transaction. Our related party transactions are settled through Fresenius SE's cash management system where appropriate.
	a)       Service and Lease Agreements
	The Company is party to service agreements with Fresenius SE and certain of its affiliates (collectively the “Fresenius SE Companies”) to receive services, including, but not limited to: administrative services, management information services, employee benefit administration, insurance, information technology services, tax services and treasury management services. During the three-months ended March 31, 2014 and 2013, amounts charged by Fresenius SE Companies to the Company under the terms of these agreements were $27,467 and $23,973, respectively. The Company also provides certain services to the Fresenius SE Companies, including research and development, central purchasing and warehousing. The Company charged $1,848 and $1,719 for services rendered to the Fresenius SE Companies during the first three months of 2014 and 2013 respectively.
	Under real estate operating lease agreements entered into with the Fresenius SE Companies, which are leases for the corporate headquarters in Bad Homburg, Germany and production sites in Schweinfurt and St. Wendel, Germany, the Company paid the Fresenius SE Companies $7,038 and $6,569 during the three months ended March 31, 2014 and 2013, respectively. The majority of the leases expire in 2016 and contain renewal options.
	The Company's Articles of Association provide that the General Partner shall be reimbursed for any and all expenses in connection with management of the Company's business, including remuneration of the members of the General Partner's supervisory board and the members of the General Partner's management board. The aggregate amount reimbursed to the General Partner was $8,172 and $4,511, respectively, for its management services during the three months ended March 31, 2014 and 2013.
	b)       Products
	For the first three months of 2014 and 2013, the Company sold products to the Fresenius SE Companies for $7,481 and $7,215, respectively. During the same periods, the Company made purchases from the Fresenius SE Companies in the amount of $5,907 and $10,364, respectively.
	In addition to the purchases noted above, Fresenius Medical Care Holdings, Inc. (“FMCH”) currently purchases heparin supplied by Fresenius Kabi USA, Inc. (“Kabi USA”), through an independent group purchasing organization (“GPO”). Kabi USA is wholly-owned by Fresenius Kabi AG, a wholly-owned subsidiary of Fresenius SE. The Company has no direct supply agreement with Kabi USA and does not submit purchase orders directly to Kabi USA. During the three-months ended March 31, 2014 and 2013, FMCH acquired approximately $5,348 and $4,560, respectively, of heparin from Kabi USA, through the GPO contract, which was negotiated by the GPO at arm's length on behalf of all members of the GPO.
	c)       Financing
	The Company receives short-term financing from and provides short-term financing to Fresenius SE. The Company also utilizes Fresenius SE's cash management system for the settlement of certain intercompany receivables and payables with its subsidiaries and other related parties. As of March 31, 2014 and December 31, 2013, the Company had accounts receivables from Fresenius SE in the amount of $149,350 and $112,568, respectively. As of March 31, 2014 and December 31, 2013, the Company had accounts payables to Fresenius SE in the amount of $134,817 and $102,731, respectively. The interest rates for these cash management arrangements are set on a daily basis and are based on the then-prevailing overnight reference rate for the respective currencies.
	At March 31, 2014, the Company borrowed from Fresenius SE €52,700 ($72,663 at March 31, 2014) at an interest rate of 1.612%. This loan was renewed and increased to €142,300 ($197,350) at an interest rate of 1.644% and is due on May 31, 2014.
	On August 19, 2009, the Company borrowed €1,500 ($2,068 at March 31, 2014) from the General Partner at 1.335%. The loan repayment has been extended periodically and is currently due August 20, 2014 with an interest rate of 1.796%. On November 28, 2013, the Company borrowed an additional €1,500 ($2,068 at March 31, 2014) from the General Partner at 1.875%. This loan is due on November 28, 2014.
	At March 31, 2014, the Company had a Chinese Yuan Renminbi (“CNY”) loan of 357,710 ($57,515 at March 31, 2014) outstanding with a subsidiary of Fresenius SE at an interest rate of 6.1% and a maturity date of May 23, 2014.
	d) Other
	The Company performs clinical studies for certain of its joint ventures for which services the Company received $657 and $1,348 for the three months ended March 31, 2014 and 2013, respectively. In addition, the Company also performs marketing and distribution services for a joint venture for which services the Company received $4,349 and $4,006 for the three months ended March 31, 2014 and 2013, respectively.
	At March 31, 2014 and December 31, 2013, a subsidiary of Fresenius SE held Senior Notes issued by the Company in the amount of €11,800 and €11,800 ($16,270 and $16,273), respectively. The Senior Notes were issued in 2011 and 2012 and have a coupon rate of 5.25% with interest payable semiannually.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Inventories	'
	3. Inventories
	At March 31, 2014 and December 31, 2013, inventories consisted of the following:
				31-Mar-14		31-Dec-13
	Finished goods		$	751,027	$	640,355
	Raw materials and purchased components			194,808		185,146
	Health care supplies			186,687		195,519
	Work in process			74,250		76,084
		Inventories	$	1,206,772	$	1,097,104

ShortTerm_Borrowings_and_Other

Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Short-Term Borrowings and Other Financial Liabilities, and Short-Term Borrowings from Related Parties	'
	Short-Term Borrowings, Other Financial Liabilities and Short-Term Borrowings from Related Parties
	At March 31, 2014 and December 31, 2013, short-term borrowings, other financial liabilities and short-term borrowings from related parties consisted of the following:
		31-Mar-14		31-Dec-13
	Borrowings under lines of credit	$	100,429	$	95,690
	Other financial liabilities		56,797		958
	Short-term borrowings and other financial liabilities		157,226		96,648
	Short-term borrowings from related parties (see Note 2.c)		134,314		62,342
	Short-term borrowings, other financial liabilities and short-term borrowings from related parties	$	291,540	$	158,990
		31-Mar-14		31-Dec-13
	Borrowings under lines of credit	$	100,429	$	95,690
	Other financial liabilities		56,797		958
	Short-term borrowings and other financial liabilities		157,226		96,648
	Short-term borrowings from related parties (see Note 2.c)		134,314		62,342
	Short-term borrowings, other financial liabilities and short-term borrowings from related parties	$	291,540	$	158,990

Longterm_Debt_and_Capital_Leas

Long-term Debt and Capital Lease Obligations	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Long-term Debt and Capital Lease Obligations	'
	5. Long-Term Debt and Capital Lease Obligations
	At March 31, 2014 and December 31, 2013, long-term debt and capital lease obligations consisted of the following:
		31-Mar-14		31-Dec-13
	2012 Credit Agreement	$	2,910,561	$	2,707,145
	Senior Notes		4,825,384		4,824,753
	Euro Notes		46,535		46,545
	European Investment Bank Agreements (1)		-		193,074
	Accounts receivable facility		419,250		351,250
	Capital lease obligations		24,875		24,264
	Other		90,825		111,259
	Long-term debt and capital lease obligations		8,317,430		8,258,290
	Less current maturities		-301,275		-511,370
	Long-term debt and capital lease obligations, less current portion	$	8,016,155	$	7,746,920
	(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014.
		31-Mar-14		31-Dec-13
	2012 Credit Agreement	$	2,910,561	$	2,707,145
	Senior Notes		4,825,384		4,824,753
	Euro Notes		46,535		46,545
	European Investment Bank Agreements (1)		-		193,074
	Accounts receivable facility		419,250		351,250
	Capital lease obligations		24,875		24,264
	Other		90,825		111,259
	Long-term debt and capital lease obligations		8,317,430		8,258,290
	Less current maturities		-301,275		-511,370
	Long-term debt and capital lease obligations, less current portion	$	8,016,155	$	7,746,920
	(1) The remaining two loans under the European Investment Bank Agreements were repaid on their maturity in February 2014.
	2012 Credit Agreement
	The following table shows the available and outstanding amounts under the 2012 Credit Agreement at March 31, 2014 and at December 31, 2013:
		Maximum Amount Available March 31, 2014				Balance Outstanding March 31, 2014
	Revolving Credit USD	$	600,000	$	600,000	$	336,469	$	336,469
	Revolving Credit EUR	€	500,000	$	689,400	€	90,000	$	124,092
	Term Loan A	$	2,450,000	$	2,450,000	$	2,450,000	$	2,450,000
				$	3,739,400			$	2,910,561
		Maximum Amount Available December 31, 2013				Balance Outstanding December 31, 2013
	Revolving Credit USD	$	600,000	$	600,000	$	138,190	$	138,190
	Revolving Credit EUR	€	500,000	$	689,550	€	50,000	$	68,955
	Term Loan A	$	2,500,000	$	2,500,000	$	2,500,000	$	2,500,000
				$	3,789,550			$	2,707,145
	Accounts Receivable Facility
	The following table shows the available and outstanding amounts under the account receivable facility at March 31, 2014 and at December 31, 2013:
			Maximum Amount Available(1)			Balance Outstanding
		31-Mar-14		31-Dec-13		31-Mar-14		31-Dec-13
	Accounts Receivable Facility	$	800,000	$	800,000	$	419,250	$	351,250
	(1) Subject to availability of sufficient accounts receivable meeting funding criteria.
	The Company also had letters of credit outstanding under the accounts receivable facility in the amount of $65,622 as of March 31, 2014 and December 31, 2013. These letters of credit are not included above as part of the balance outstanding at March 31, 2014 and December 31, 2013; however, they reduce available borrowings under the accounts receivable facility.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Earnings Per Share	'
	6. Earnings Per Ordinary Share
	The following table contains reconciliations of the numerators and denominators of the basic and diluted earnings per ordinary share computations for the three-months ended March 31, 2014 and 2013:
			For the three months ended March 31,
			2014		2013
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA		$	205,462	$	225,499
	less:
		Dividend preference on Preference shares(1)		-		26
	Income available to all classes of shares		$	205,462	$	225,473
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding			301,491,046		302,773,218
	Preference shares outstanding(1)			-		3,973,333
	Total weighted average shares outstanding			301,491,046		306,746,551
	Potentially dilutive Ordinary shares			378,831		1,131,149
	Potentially dilutive Preference shares(1)			-		13,681
	Total weighted average Ordinary shares outstanding assuming dilution			301,869,877		303,904,367
	Total weighted average Preference shares outstanding assuming dilution(1)			-		3,987,014
	Basic income per Ordinary share		$	0.68	$	0.74
	Fully diluted income per Ordinary share			0.68		0.73
	(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding.

Employee_Benefit_Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Employee Benefit Plans	'
	7. Employee Benefit Plans
	The Company currently has two principal pension plans, one for German employees, the other covering employees in the United States, the latter of which was curtailed in 2002. Plan benefits are generally based on years of service and final salary. As there is no legal requirement in Germany to fund defined benefit plans, the Company's pension obligations in Germany are unfunded. Each year FMCH contributes to the plan covering United States employees at least the minimum required by the Employee Retirement Income Security Act of 1974, as amended.
	The following table provides the calculations of net periodic benefit cost for the three-months ended March 31, 2014 and 2013, respectively.
		For the three months ended March 31,
		2014		2013
	Components of net periodic benefit cost:
	Service cost	$	4,739	$	3,913
	Interest cost		7,404		6,784
	Expected return on plan assets		-3,925		-3,400
	Amortization of unrealized losses		4,354		6,398
	Net periodic benefit costs	$	12,572	$	13,695

Noncontrolling_Interests_Subje

Noncontrolling Interests Subject to Put Provisions	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	8. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At March 31, 2014 and December 31, 2013, the Company's potential obligations under these put options were $631,940 and $648,251, respectively, of which, at March 31, 2014, put options with an aggregate purchase obligation of $251,453 were exercisable. No put options were exercised during the first three months of 2014.
	The following is a roll forward of noncontrolling interests subject to put provisions for the three months ended March 31, 2014 and the year ended December 31, 2013:
		31-Mar-14		31-Dec-13
	Beginning balance as of January 1,	$	648,251	$	523,260
	Contributions to noncontrolling interests		-29,121		-122,179
	Purchase/ sale of noncontrolling interests		-4,452		6,723
	Contributions from noncontrolling interests		4,329		17,767
	Changes in fair value of noncontrolling interests		-13,847		108,575
	Net income		26,768		113,156
	Other comprehensive income (loss)		12		949
	Ending balance as of March 31, 2014 and December 31, 2013	$	631,940	$	648,251

Patient_Service_Revenue

Patient Service Revenue	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Patient Service Revenue Text Block 1 [Text Block]	'
	9. Sources of Revenue
	Below is a table showing the sources of our U.S. patient service revenue (net of contractual allowance and discounts but before patient service bad debt provision), included in the Company's dialysis care revenue, for the three-months ended March 31, 2014 and 2013. Outside of the U.S., the Company does not recognize patient service revenue at the time the services are rendered without assessing the patient's ability to pay. Accordingly, the additional disclosure requirements introduced with ASU 2011-07 only apply to the U.S. patient service revenue.
		For the three months ended March 31,
			2014		2013
	Medicare ESRD program	$	1,094,338	$	1,055,056
	Private/alternative payors		947,477		914,397
	Medicaid and other government sources		109,486		91,026
	Hospitals		112,701		106,931
	Total patient service revenue	$	2,264,002	$	2,167,410

Financial_Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Financial Instruments	'
	11. Financial Instruments
	Non-derivative Financial Instruments
	The following table presents the carrying amounts and fair values of the Company's non-derivative financial instruments at March 31, 2014, and December 31, 2013.
						March 31,						December 31,
						2014						2013
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	574,127			574,127		$	682,777			682,777
		Accounts Receivable(1)	2			3,251,520			3,251,520			3,190,392			3,190,392
		Notes Receivable	3			166,631			184,242			165,807			175,768
	Liabilities
		Accounts payable(1)	2			714,897			714,897			666,526			666,526
		Short-term borrowings(1)	2			291,540			291,540			158,990			158,990
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			534,950			534,950			679,847			679,847
		2012 Credit Agreement	2			2,910,561			2,910,561			2,707,145			2,710,270
		Senior Notes	2			4,825,384			5,332,253			4,824,753			5,348,679
		Euro Notes	2			46,535			46,722			46,545			47,423
	Noncontrolling interests subject to put provisions		3			631,940			631,940			648,251			648,251
	(1) Also includes amounts receivable from or payable to related parties.
	The carrying amounts in the table are included in the consolidated balance sheet under the indicated captions or in the case of long-term debt, in the captions shown in Note 5.
	The significant methods and assumptions used in estimating the fair values of non-derivative financial instruments are as follows:
	Cash and cash equivalents are stated at nominal value which equals the fair value.
	Short-term financial instruments such as accounts receivable, accounts payable and short-term borrowings are valued at their carrying amounts, which are reasonable estimates of the fair value due to the relatively short period to maturity of these instruments.
	The valuation of notes receivable was determined using significant unobservable inputs. They were valued using a constructed index based upon similar instruments with comparable credit ratings, terms, tenor, interest rates and that are within the Company's industry. The Company tracked the prices of the constructed index from the note issuance date to the reporting date to determine fair value.
	The fair values of major long-term financial liabilities are calculated on the basis of market information. Instruments for which market quotes are available are measured using these quotes. The fair values of the other long-term financial liabilities are calculated at the present value of the respective future cash flows. To determine these present values, the prevailing interest rates and credit spreads for the Company as of the balance sheet date are used.
	The valuation of noncontrolling interests subject to put provisions is determined using significant unobservable inputs. See Note 8 for a discussion of the Company's methodology for estimating the fair value of these noncontrolling interests subject to put obligations.
	Currently, there is no indication that a decrease in the value of the Company's financing receivables is probable. Therefore, the allowances on credit losses of financing receivables are immaterial.
	Derivative Financial Instruments
	The Company is exposed to market risk from changes in foreign exchange rates and interest rates. In order to manage the risk of currency exchange rate and interest rate fluctuations, the Company enters into various hedging transactions by means of derivative instruments with highly rated financial institutions as authorized by the Company's General Partner. On a quarterly basis the Company performs an assessment of its counterparty credit risk. The Company currently considers this risk to be low. The Company's policy, which has been consistently followed, is that financial derivatives be used only for the purpose of hedging foreign currency and interest rate exposure.
	In certain instances, the Company enters into derivative contracts that do not qualify for hedge accounting but are utilized for economic purposes (“economic hedges”). The Company does not use financial instruments for trading purposes.
	The Company established guidelines for risk assessment procedures and controls for the use of financial instruments. They include a clear segregation of duties with regard to execution on one side and administration, accounting and controlling on the other.
	To reduce the credit risk arising from derivatives the Company concluded Master Netting Agreements with banks. Through such agreements, positive and negative fair values of the derivative contracts could be offset against one another if a partner becomes insolvent. This offsetting is valid for transactions where the aggregate amount of obligations owed to and receivable from are not equal. If insolvency occurs, the party which owes the larger amount is obliged to pay the other party the difference between the amounts owed in the form of one net payment.
	The Company elects not to offset the fair values of derivative financial instruments subject to master netting agreements in its Consolidated Balance Sheets.
	At March 31, 2014 and December 31, 2013, the Company had $19,048 and $18,334 of derivative financial assets subject to netting arrangements and $14,044 and $16,371 of derivative financial liabilities subject to netting arrangements. Offsetting these derivative financial instruments would have resulted in net assets of $11,996 and $12,169 as well as net liabilities of $6,992 and $10,207 at March 31, 2014 and December 31, 2013, respectively.
	Foreign Exchange Risk Management
	The Company conducts business on a global basis in various currencies, though a majority of its operations are in Germany and the United States. For financial reporting purposes, the Company has chosen the U.S. dollar as its reporting currency. Therefore, changes in the rate of exchange between the U.S. dollar and the local currencies in which the financial statements of the Company's international operations are maintained affect its results of operations and financial position as reported in its consolidated financial statements.
	The Company's exposure to market risk for changes in foreign exchange rates relates to transactions such as sales and purchases. The Company has significant amounts of sales of products invoiced in euro from its European manufacturing facilities to its other international operations and, to a lesser extent, sales of products invoiced in other non-functional currencies. This exposes the subsidiaries to fluctuations in the rate of exchange between the euro and the currency in which their local operations are conducted. For the purpose of hedging existing and foreseeable foreign exchange transaction exposures the Company enters into foreign exchange forward contracts and, on a small scale, foreign exchange options. At March 31, 2014 and December 31, 2013, the Company had no foreign exchange options.
	Changes in the fair value of the effective portion of foreign exchange forward contracts designated and qualifying as cash flow hedges of forecasted product purchases and sales are reported in Accumulated Other Comprehensive Income (“AOCI”). Additionally, in connection with intercompany loans in foreign currency, the Company uses foreign exchange swaps thus assuring that no foreign exchange risks arise from those loans, which, if they qualify for cash flow hedge accounting, are also reported in AOCI. These amounts recorded in AOCI are subsequently reclassified into earnings as a component of cost of revenues for those contracts that hedge product purchases or as an adjustment of interest income/expense for those contracts that hedge loans, in the same period in which the hedged transaction affects earnings. The notional amounts of foreign exchange contracts in place that are designated and qualify as cash flow hedges totaled $174,918 and $238,983 at March 31, 2014 and December 31, 2013, respectively.
	The Company also enters into derivative contracts for forecasted product purchases and sales and for intercompany loans in foreign currency that do not qualify for hedge accounting but are utilized for economic hedges as defined above. In these two cases, the change in value of the economic hedge is recorded in the income statement and usually offsets the change in value recorded in the income statement for the underlying asset or liability. The notional amounts of economic hedges that do not qualify for hedge accounting totaled $1,685,750 and $1,512,559 at March 31, 2014 and December 31, 2013, respectively.
	Interest Rate Risk Management
	The Company enters into derivatives, particularly interest rate swaps and to a certain extent, interest rate options, to protect against the risk of rising interest rates. These interest rate derivatives are designated as cash flow hedges and have been entered into in order to effectively convert payments based on variable interest rates into payments at a fixed interest rate. The euro-denominated interest rate swaps expire in 2016 and have an interest rate of 1.73%. Interest payable and receivable under the swap agreements is accrued and recorded as an adjustment to interest expense.
	At March 31, 2014 and December 31, 2013, the notional amount of the euro-denominated interest rate swaps in place was €100,000 and €100,000 ($137,880 and $137,910 at March 31, 2014 and December 31, 2013, respectively).
	In addition, the Company also enters into interest rate hedges (“pre-hedges”) in anticipation of future debt issuance to effectively convert the variable interest rate related to the future debt to a fixed interest rate. These pre-hedges are settled at the issuance date of the corresponding debt with the settlement amount recorded in AOCI amortized to interest expense over the life of the pre-hedges. At March 31, 2014 and December 31, 2013, the Company had $113,570 and $118,844, respectively, related to such settlements of pre-hedges deferred in AOCI, net of tax.
	Derivative Financial Instruments Valuation
	The following table shows the carrying amounts of the Company's derivatives at March 31, 2014 and December 31, 2013.
				31-Mar-14						31-Dec-13
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		3,235			-2,856			4,985			-2,719
		Non-current
			Foreign exchange contracts		204			-			759			-374
			Interest rate contracts		-			-4,553			-			-4,392
	Total			$	3,439		$	-7,409		$	5,744		$	-7,485
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		15,373			-15,449			11,679			-22,982
		Non-current
			Foreign exchange contracts		556			-648			1,060			-820
	Total			$	15,929		$	-16,097		$	12,739		$	-23,802
	(1) At March 31, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
The carrying amounts for the current portion of derivatives indicated as assets in the table above are included in Prepaid expenses and other current assets in the Consolidated Balance Sheets while the current portion of those indicated as liabilities are included in Accrued expenses and other current liabilities. The non-current portions indicated as assets or liabilities are included in the Consolidated Balance Sheets in Other assets or Other liabilities, respectively.
The significant methods and assumptions used in estimating the fair values of derivative financial instruments are as follows:
The fair value of interest rate swaps is calculated by discounting the future cash flows on the basis of the market interest rates applicable for the remaining term of the contract as of the balance sheet date. To determine the fair value of foreign exchange forward contracts, the contracted forward rate is compared to the current forward rate for the remaining term of the contract as of the balance sheet date. The result is then discounted on the basis of the market interest rates prevailing at the balance sheet date for the applicable currency.
The Company includes its own credit risk for financial instruments deemed liabilities and counterparty-credit risks for financial instruments deemed assets when measuring the fair value of derivative financial instruments.
The Effect of Derivatives on the Consolidated Financial Statements
			Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
Derivatives in Cash Flow Hedging Relationships
			(Effective Portion) for the three months ended March 31,										(Effective Portion) for the three months ended March 31,
			2014			2013		(Effective Portion)				2014			2013
Interest rate contracts		$	-125		$	6,470		Interest income/expense			$	7,358		$	6,365
Foreign exchange contracts			-845			3,991		Costs of Revenue				571			-1,345
Foreign exchange contracts								Interest income/expense				-			416
		$	-970		$	10,461					$	7,929		$	5,436
Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives for the three months ended March 31,
			Location of (Gain) or Loss Recognized in Income on Derivative
						2014			2013
Foreign exchange contracts			Selling, general and administrative expense		$	-2,298		$	-21,812
Foreign exchange contracts			Interest income/expense			1,226			1,966
					$	-1,072		$	-19,846
For foreign exchange derivatives, the Company expects to recognize $372 of losses deferred in AOCI at March 31, 2014, in earnings during the next twelve months.
The Company expects to incur additional interest expense of $23,303 over the next twelve months which is currently deferred in AOCI. At March 31, 2014, this amount reflects the projected amortization of the settlement amount of the terminated swaps and the current fair value of the additional interest payments resulting from the remaining interest rate swap maturing in 2016.
At March 31, 2014, the Company had foreign exchange derivatives with maturities of up to 20 months and interest rate swaps with maturities of up to 31 months.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Commitments and Contingencies	'
	Legal and Regulatory Matters
	The Company is routinely involved in numerous claims, lawsuits, regulatory and tax audits, investigations and other legal matters arising, for the most part, in the ordinary course of its business of providing healthcare services and products. Legal matters that the Company currently deems to be material are described below. For the matters described below in which the Company believes a loss is both reasonably possible and estimable, an estimate of the loss or range of loss exposure is provided. For the other matters described below, the Company believes that the loss probability is remote and/or the loss or range of possible losses cannot be reasonably estimated at this time. The outcome of litigation and other legal matters is always difficult to predict accurately and outcomes that are not consistent with the Company's view of the merits can occur. The Company believes that it has valid defenses to the legal matters pending against it and is defending itself vigorously. Nevertheless, it is possible that the resolution of one or more of the legal matters currently pending or threatened could have a material adverse effect on its business, results of operations and financial condition.
	Commercial Litigation
	On April 4, 2003, FMCH filed a suit in the U. S. District Court for the Northern District of California, styled Fresenius USA, Inc., et al., v. Baxter International Inc., et al., Case No. C 03-1431, seeking a declaratory judgment that FMCH does not infringe patents held by Baxter International Inc. and its subsidiaries and affiliates (“Baxter”), that the patents are invalid, and that Baxter is without right or authority to threaten or maintain suit against FMCH for alleged infringement of Baxter's patents. In general, the asserted patents concern the use of touch screen interfaces for hemodialysis machines. Baxter filed counterclaims against FMCH seeking more than $140,000 in monetary damages and injunctive relief, and alleging that FMCH willfully infringed on Baxter's patents. On July 17, 2006, the court entered judgment on a jury verdict in favor of FMCH finding all asserted claims of Baxter patents invalid as obvious and/or anticipated in light of prior art.
	On February 13, 2007, the court granted Baxter's motion to set aside the jury's verdict in favor of FMCH and reinstated the patents and entered judgment of infringement. Following a trial on damages, the court entered judgment on November 6, 2007 in favor of Baxter on a jury award of $14,300. On April 4, 2008, the court denied Baxter's motion for a new trial, established a royalty payable to Baxter of 10% of the sales price for continuing sales of FMCH's 2008K hemodialysis machines and 7% of the sales price of related disposables, parts and service beginning November 7, 2007, and enjoined sales of the touchscreen-equipped 2008K machine effective January 1, 2009. The Company appealed the court's rulings to the United States Court of Appeals for the Federal Circuit (“Federal Circuit”). On September 10, 2009, the Federal Circuit reversed the district court's decision and determined that the asserted claims in two of the three patents at issue are invalid. As to the third patent, the Federal Circuit affirmed the district court's decision; however, the Court also vacated the injunction and award of damages. These issues were remanded to the District Court for reconsideration in light of the invalidity ruling on most of the claims. Upon remand, the district court reduced the post-verdict damages award to $10,000. Separately, the U.S. Patent and Trademark Office (“USPTO”) and the Board of Patent Appeals and Interferences ruled that the remaining Baxter patent is invalid. On May 17, 2012 the Federal Circuit affirmed the USPTO's ruling and invalidated the final remaining Baxter patent. Baxter appealed to the Federal Circuit claiming that approximately $20,000 of damages awarded to it by the District Court before the Federal Circuit affirmed the USPTO ruling constituted a final judgment that may be collected. On July 2, 2013, the Federal Circuit denied Baxter's appeal and ordered the District Court to dismiss the case. The court-approved escrow account has been terminated and the escrow funds have been returned to FMCH. On March 5, 2014, Baxter petitioned the United States Supreme Court to review the decisions of the Federal Circuit.
	On August 27, 2012, Baxter filed suit in the U.S. District Court for the Northern District of Illinois, styled Baxter International Inc., et al., v. Fresenius Medical Care Holdings, Inc., Case No. 12-cv-06890, alleging that the Company's LibertyTM cycler infringes certain U.S. patents that were issued to Baxter between October 2010 and June 2012. The Company believes it has valid defenses to these claims, and will defend this litigation vigorously.
	On April 5, 2013, the U.S. Judicial Panel on Multidistrict Litigation ordered that the numerous lawsuits filed and anticipated to be filed in various federal courts alleging wrongful death and personal injury claims against FMCH and certain of its affiliates relating to FMCH's acid concentrate products NaturaLyte® and Granuflo® be transferred and consolidated for pretrial management purposes into a consolidated multidistrict litigation in the United States District Court for the District of Massachusetts, styled In Re: Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigation, Case No. 2013-md-02428. The Massachusetts state courts subsequently established a similar consolidated litigation for such cases filed in Massachusetts county courts, styled In Re: Consolidated Fresenius Cases, Case No. MICV 2013-03400-O (Massachusetts Superior Court, Middlesex County). These lawsuits allege generally that inadequate labeling and warnings for these products caused harm to patients. In addition, similar cases have been filed in state courts outside Massachusetts, in some of which the judicial authorities have established consolidated proceedings for their disposition. FMCH believes that these lawsuits are without merit, and will defend them vigorously.
	Other Litigation and Potential Exposures
	On February 15, 2011, a qui tam relator's complaint under the False Claims Act against FMCH was unsealed by order of the United States District Court for the District of Massachusetts and served by the relator. The United States has not intervened in the case United States ex rel. Chris Drennen v. Fresenius Medical Care Holdings, Inc., 2009 Civ. 10179 (D. Mass.). The relator's complaint, which was first filed under seal in February 2009, alleges that the Company seeks and receives reimbursement from government payors for serum ferritin and hepatitis B laboratory tests that are medically unnecessary or not properly ordered by a physician. On March 6, 2011, the United States Attorney for the District of Massachusetts issued a subpoena seeking the production of documents related to the same laboratory tests that are the subject of the relator's complaint. FMCH has cooperated fully in responding to the subpoena, and will vigorously contest the relator's complaint.
	Subpoenas or search warrants have been issued by federal and state law enforcement authorities under the supervision of the United States Attorneys for the Districts of Connecticut, Southern Florida, Eastern Virginia and Rhode Island to American Access Care LLC (AAC), which the Company acquired in October 2011, and to the Company's Fresenius Vascular Access subsidiary which now operates former AAC centers as well as its own original facilities. Subpoenas have also been issued to certain of the Company's outpatient hemodialysis facilities for records relating to vascular access treatment and monitoring. The Company is cooperating fully in these investigations. Communications with certain of the investigating United States Attorney Offices indicate that the inquiry encompasses invoicing and coding for procedures commonly performed in vascular access centers and the documentary support for the medical necessity of such procedures. The AAC acquisition agreement contains customary indemnification obligations with respect to breaches of representations, warranties or covenants and certain other specified matters. As of October 18, 2013, a group of the prior owners of AAC exercised their right pursuant to the terms of the acquisition agreement to assume responsibility for responding to certain of the subpoenas. Pursuant to the AAC acquisition agreement the prior owners are obligated to indemnify the Company for certain liabilities that might arise from those subpoenas.
	The Company has received communications alleging certain conduct in certain countries outside the U.S. and Germany that may violate the U.S. Foreign Corrupt Practices Act (“FCPA”) or other anti-bribery laws. The Audit and Corporate Governance Committee of the Company's Supervisory Board is conducting an internal review with the assistance of independent counsel retained for such purpose. The Company voluntarily advised the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) that allegations have been made and of the Company's internal review. The Company's review and dialogue with the SEC and DOJ are ongoing.
	The review has identified conduct that raises concerns under the FCPA or other anti-bribery laws that may result in monetary penalties or other sanctions. In addition, the Company's ability to conduct business in certain jurisdictions could be negatively impacted. The Company has recorded a non-material accrual for an identified matter. Given the current status of the internal review, the Company cannot reasonably estimate the range of possible loss that may result from additional identified matters or from the final outcome of the continuing internal review.
	The Company's independent counsel, in conjunction with the Company's Compliance Department, have reviewed the Company's anti-corruption compliance program, including internal controls related to compliance with international anti-bribery laws, and appropriate enhancements are being implemented. The Company is fully committed to FCPA compliance.
	In December 2012 and January 2013, FMCH received subpoenas from the United States Attorneys for the District of Massachusetts and the Western District of Louisiana requesting production of a broad range of documents. Communications with the investigating United States Attorney Offices indicate that the inquiry relates to products manufactured by FMCH, which encompasses the Granuflo® and Naturalyte® acid concentrate products that are also the subject of personal injury litigation described above, as well as electron-beam sterilization of dialyzers, the Liberty peritoneal dialysis cycler, and 2008 series hemodialysis machines as related to the use of Granuflo® and Naturalyte®. FMCH is cooperating fully in the government's investigation.
	The Company filed claims for refunds contesting the Internal Revenue Service's (“IRS”) disallowance of FMCH's deductions for civil settlement payments taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, the Company received a partial refund in September 2008 of $37,000, inclusive of interest and preserved its right to pursue claims in the United States Courts for refunds of all other disallowed deductions, which totaled approximately $126,000. On December 22, 2008, the Company filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On August 15, 2012, a jury entered a verdict for FMCH granting additional deductions of $95,000. On May 31, 2013, the District Court entered final judgment for FMCH in the amount of $50,400. On September 18, 2013, the IRS appealed the District Court's ruling to the United States Court of Appeals for the First Circuit (Boston).
	From time to time, the Company is a party to or may be threatened with other litigation or arbitration, claims or assessments arising in the ordinary course of its business. Management regularly analyzes current information including, as applicable, the Company's defenses and insurance coverage and, as necessary, provides accruals for probable liabilities for the eventual disposition of these matters.
	The Company, like other healthcare providers, conducts its operations under intense government regulation and scrutiny. It must comply with regulations which relate to or govern the safety and efficacy of medical products and supplies, the marketing and distribution of such products, the operation of manufacturing facilities, laboratories and dialysis clinics, and environmental and occupational health and safety. With respect to its development, manufacture, marketing and distribution of medical products, if such compliance is not maintained, the Company could be subject to significant adverse regulatory actions by the FDA and comparable regulatory authorities outside the U.S. These regulatory actions could include warning letters or other enforcement notices from the FDA, and/or comparable foreign regulatory authority which may require the Company to expend significant time and resources in order to implement appropriate corrective actions. If the Company does not address matters raised in warning letters or other enforcement notices to the satisfaction of the FDA and/or comparable regulatory authorities outside the U.S., these regulatory authorities could take additional actions, including product recalls, injunctions against the distribution of products or operation of manufacturing plants, civil penalties, seizures of the Company's products and/or criminal prosecution. FMCH is currently engaged in remediation efforts with respect to three pending FDA warning letters. See “Regulatory and Legal Matters – Product Regulation” section of the 2013 Annual Report on Form 20-F for additional information. The Company must also comply with the laws of the United States, including the federal Anti-Kickback Statute, the federal False Claims Act, the federal Stark Law and the federal Foreign Corrupt Practices Act as well as other federal and state fraud and abuse laws. Applicable laws or regulations may be amended, or enforcement agencies or courts may make interpretations that differ from the Company's interpretations or the manner in which it conducts its business. Enforcement has become a high priority for the federal government and some states. In addition, the provisions of the False Claims Act authorizing payment of a portion of any recovery to the party bringing the suit encourage private plaintiffs to commence “qui tam” or “whistle blower” actions. In May 2009, the scope of the False Claims Act was expanded and additional protections for whistle blowers and procedural provisions to aid whistle blowers' ability to proceed in a False Claims Act case were added. By virtue of this regulatory environment, the Company's business activities and practices are subject to extensive review by regulatory authorities and private parties, and continuing audits, subpoenas, other inquiries, claims and litigation relating to the Company's compliance with applicable laws and regulations. The Company may not always be aware that an inquiry or action has begun, particularly in the case of “whistle blower” actions, which are initially filed under court seal.
	The Company operates many facilities throughout the United States and other parts of the world. In such a decentralized system, it is often difficult to maintain the desired level of oversight and control over the thousands of individuals employed by many affiliated companies. The Company relies upon its management structure, regulatory and legal resources, and the effective operation of its compliance program to direct, manage and monitor the activities of these employees. On occasion, the Company may identify instances where employees or other agents deliberately, recklessly or inadvertently contravene the Company's policies or violate applicable law. The actions of such persons may subject the Company and its subsidiaries to liability under the Anti-Kickback Statute, the Stark Law, the False Claims Act and the Foreign Corrupt Practices Act, among other laws and comparable laws of other countries.
	Physicians, hospitals and other participants in the healthcare industry are also subject to a large number of lawsuits alleging professional negligence, malpractice, product liability, worker's compensation or related claims, many of which involve large claims and significant defense costs. The Company has been and is currently subject to these suits due to the nature of its business and expects that those types of lawsuits may continue. Although the Company maintains insurance at a level which it believes to be prudent, it cannot assure that the coverage limits will be adequate or that insurance will cover all asserted claims. A successful claim against the Company or any of its subsidiaries in excess of insurance coverage could have a material adverse effect upon it and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business.
	The Company has also had claims asserted against it and has had lawsuits filed against it relating to alleged patent infringements or businesses that it has acquired or divested. These claims and suits relate both to operation of the businesses and to the acquisition and divestiture transactions. The Company has, when appropriate, asserted its own claims, and claims for indemnification. A successful claim against the Company or any of its subsidiaries could have a material adverse effect upon its business, financial condition, and the results of its operations. Any claims, regardless of their merit or eventual outcome, could have a material adverse effect on the Company's reputation and business

Business_Segment_Information

Business Segment Information	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Business Segment Information	'
	13. Segment and Corporate Information
	The Company has identified three operating segments, North America Segment, EMEALA and Asia-Pacific, which were determined based upon how the Company manages its businesses. All segments are primarily engaged in providing dialysis care services and the distribution of products and equipment for the treatment of ESRD. For reporting purposes, the Company has aggregated the EMEALA and Asia-Pacific operating segments as the “International Segment.” The segments are aggregated due to their similar economic characteristics. These characteristics include same services provided and same products sold, the same type of patient population, similar methods of distribution of products and services and similar economic environments. The General Partner's management board member responsible for the profitability and cash flow of each segment's various businesses supervises the management of each operating segment. The accounting policies of the segments are the same as those the Company applies in preparing the consolidated financial statements under U.S. GAAP.
	Management evaluates each segment using measures that reflect all of the segment's controllable revenues and expenses. With respect to the performance of business operations, management believes that the most appropriate U.S. GAAP measures are revenue, operating income and operating income margin. The Company does not include income taxes as it believes this is outside the segments' control. Financing is a corporate function, which the Company's segments do not control. Therefore, the Company does not include interest expense relating to financing as a segment measurement. Similarly, the Company does not allocate certain costs, which relate primarily to certain headquarters overhead charges, including accounting and finance, etc. (“Corporate”), because the Company believes that these costs are also not within the control of the individual segments. Production of products, production asset management, quality management and procurement are centrally managed at Corporate by Global Manufacturing Operations. The Company's global research and development is also centrally managed at Corporate. These Corporate activities do not fulfill the definition of a segment. Products are transferred to the segments at cost; therefore no internal profit is generated. The associated internal revenues for the product transfers and their elimination are recorded as Corporate activities. Capital expenditures for production are based on the expected demand of the segments and consolidated profitability considerations. In addition, certain revenues, investments and intangible assets, as well as any related expenses, are not allocated to a segment but accounted for as Corporate.
	Information pertaining to the Company's segment and Corporate activities for the three-months periods ended March 31, 2014 and 2013 is set forth below.
					North America Segment		International Segment		Segment Totals		Corporate		Total
	Three months ended March 31, 2014
		Net revenue external customers		$	2,392,907	$	1,160,898	$	3,553,805	$	9,787	$	3,563,592
		Inter - segment revenue			1,280		-		1,280		-1,280		-
		Revenue			2,394,187		1,160,898		3,555,085		8,507		3,563,592
		Depreciation and amortization			-87,649		-45,021		-132,670		-34,497		-167,167
		Operating income			335,562		180,446		516,008		-71,113		444,895
		Income (loss) from equity method investees			10,551		1,971		12,522		-		12,522
		Segment assets			14,860,218		6,267,649		21,127,867		2,294,810		23,422,677
			thereof investments in equity method investees		300,110		433,802		733,912		-		733,912
		Capital expenditures, acquisitions and investments (1)			204,899		64,637		269,536		67,252		336,788
	Three months ended March 31, 2013
		Net revenue external customers		$	2,287,250	$	1,168,652	$	3,455,902	$	8,019	$	3,463,921
		Inter - segment revenue			1,075		-		1,075		-1,075		-
		Revenue			2,288,325		1,168,652		3,456,977		6,944		3,463,921
		Depreciation and amortization(2)			-80,407		-45,900		-126,307		-30,046		-156,353
		Operating income (3)			366,048		191,617		557,665		-64,352		493,313
		Income (loss) from equity method investees(4)			3,118		1,690		4,808		-		4,808
		Segment assets			14,044,466		5,896,442		19,940,908		2,198,755		22,139,663
			thereof investments in equity method investees		239,689		361,738		601,427		-		601,427
		Capital expenditures, acquisitions and investments (5)			112,332		82,702		195,034		24,537		219,571
		(1) International acquisitions exclude $7,569 of non-cash acquisitions for 2014.
		(2) Depreciation in the amount of $895 relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(3) Certain items, in the net aggregate amount of $5,006, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable.
		(4) Income (loss) from equity method investees in the amount of $396 has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(5) International acquisitions exclude $3,690 of non-cash acquisitions for 2013.

Other_Comprehensive_Income

Other Comprehensive Income	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Other Comprehensive Income	'
	12. Other Comprehensive Income (Loss), net of tax
	Changes in AOCI, net of tax, by component for the three months ended March 31, 2014 and 2013 are as follows:
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (Loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		8,031			-			-66,210		-58,179		-1,982		-60,161
		Amounts reclassified from AOCI		3,639			3,941			-		7,580		-		7,580
	Other comprehensive income (loss) after reclassifications			11,670			3,941			-66,210		-50,599		-1,982		-52,581
	Balance at March 31, 2013		$	-126,671		$	-175,482		$	-240,559	$	-542,712	$	887	$	-541,825
	Balance at December 31, 2013		$	-121,856		$	-141,987		$	-286,744	$	-550,587	$	825	$	-549,762
		Other comprehensive income (loss) before reclassifications		-556			-			-47,023		-47,579		-33		-47,612
		Amounts reclassified from AOCI		5,579			2,740			-		8,319		-		8,319
	Other comprehensive income (loss) after reclassifications			5,023			2,740			-47,023		-39,260		-33		-39,293
	Balance at March 31, 2014		$	-116,833		$	-139,247		$	-333,767	$	-589,847	$	792	$	-589,055
	Reclassifications out of AOCI for the three months ended March 31, 2014 and 2013 are as follows:
	Details about AOCI Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the three months ended March 31,
				2014			2013
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	7,358		$	6,365		Interest income/expense
		Foreign exchange contracts			571			-1,345		Costs of Revenue
		Foreign exchange contracts			-			416		Interest income/expense
					7,929			5,436		Total before tax
					-2,350			-1,797		Tax expense or benefit
				$	5,579		$	3,639		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) /loss			4,354			6,398		-1
					4,354			6,398		Total before tax
					-1,614			-2,457		Tax expense or benefit
				$	2,740		$	3,941		Net of tax
	Total reclassifications for the period			$	8,319		$	7,580		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 7 for additional details).

Supplementary_Cash_Flow_Inform

Supplementary Cash Flow Information	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Cash Flow Supplemental Disclosures [Text Block]	'
	14. Supplementary Cash Flow Information
	The following additional information is provided with respect to the consolidated statements of cash flows:
			Three months ended March 31,
			2014		2013
	Supplementary cash flow information:
		Cash paid for interest	$	164,393	$	165,596
		Cash paid for income taxes (1)	$	83,138	$	59,708
		Cash inflow for income taxes from stock option exercises	$	545	$	522
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-31,589	$	-69,485
		Liabilities assumed		2,251		3,334
		Noncontrolling interest subject to put provisions		-		6,294
		Noncontrolling interest		288		4,527
		Obligations assumed in connection with acquisition		7,569		3,690
		Cash paid		-21,481		-51,640
		Less cash acquired		105		2,530
		Net cash paid for acquisitions		-21,376		-49,110
		Cash paid for investments		-112,848		-22,185
		Cash paid for intangible assets		-2,933		-919
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-137,157	$	-72,214
		(1) Net of tax refund.

Supplemental_Condensed_Combini

Supplemental Condensed Combining Information	3 Months Ended
	Mar. 31, 2014
Notes to Consolidated Financial Statements [Abstract]	'
Supplemental Condensed Combining Information	'
	16. Supplemental Condensed Combining Information
	FMC Finance III, a former wholly-owned subsidiary of the Company, issued 6⅞% Senior Notes due 2017 in July 2007. On June 20, 2011, Fresenius Medical Care US Finance, Inc. (“US Finance”) acquired substantially all of the assets of FMC Finance III and assumed its obligations, including the 6⅞% Senior Notes and the related indenture. The 6⅞% Senior Notes are fully and unconditionally guaranteed, jointly and severally on a senior basis, by the Company and by FMCH and Fresenius Medical Care Deutschland GmbH (“D-GmbH”), together the (“Guarantor Subsidiaries”). The 6⅞% Senior Notes and related guarantees were issued in an exchange offer registered under the Securities Act of 1933. The financial statements in this report present the financial condition, results of operations and cash flows of the Company, on a consolidated basis at March 31, 2014 and December 31, 2013 and for the three-months periods ended March 31, 2014 and 2013. The following combining financial information for the Company is at March 31, 2014 and December 31, 2013 and for the three-months periods ended March 31, 2014 and 2013, segregated between FMC US Finance as issuer, the Company, D-GmbH and FMCH as guarantors, and the Company's other businesses (the “Non-Guarantor Subsidiaries”). For purposes of the condensed combining information, the Company and the Guarantor Subsidiaries carry their investments under the equity method. Other (income) expense includes income (loss) related to investments in consolidated subsidiaries recorded under the equity method for purposes of the condensed combining information. In addition, other (income) expense includes income and losses from profit and loss transfer agreements as well as dividends received.
			For the three months ended March 31, 2014
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	531,730		$	-		$	3,896,574		$	-864,712		$	3,563,592
	Cost of revenue			-			-			332,156			-			2,995,003			-845,699			2,481,460
		Gross profit		-			-			199,574			-			901,571			-19,013			1,082,132
	Operating expenses (income):
		Selling, general and administrative(1)		-			47,374			28,650			-26,380			569,452			-11,887			607,209
		Research and development		-			-			19,297			-			10,731			-			30,028
	Operating (loss) income			-			-47,374			151,627			26,380			321,388			-7,126			444,895
	Other (income) expense:
		Interest, net		-1,731			60,526			-1,031			45,462			-7,015			50			96,261
		Other, net		-			-330,870			111,665			-154,698			-			373,903			-
	Income (loss) before income taxes			1,731			222,970			40,993			135,616			328,403			-381,079			348,634
		Income tax expense (benefit)		628			17,508			37,172			-7,528			148,579			-95,075			101,284
	Net Income (loss)			1,103			205,462			3,821			143,144			179,824			-286,004			247,350
	Net Income attributable to noncontrolling interests			-			-			-			-			-			41,888			41,888
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-327,892		$	205,462
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the three months ended March 31, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	495,497		$	-		$	3,758,626		$	-790,202		$	3,463,921
	Cost of revenue			-			-			335,779			-			2,796,879			-778,255			2,354,403
		Gross profit		-			-			159,718			-			961,747			-11,947			1,109,518
	Operating expenses (income):
		Selling, general and administrative (1)		-			6,423			49,086			-7,180			511,647			25,857			585,833
		Research and development		-			-			17,969			-			12,572			-169			30,372
	Operating (loss) income			-			-6,423			92,663			7,180			437,528			-37,635			493,313
	Other (income) expense:
		Interest, net		-1,697			46,193			2,251			40,298			17,184			-			104,229
		Other, net		-			-263,397			96,047			-181,689			-			349,039			-
	Income (loss) before income taxes			1,697			210,781			-5,635			148,571			420,344			-386,674			389,084
		Income tax expense (benefit)		616			-14,718			6,076			-13,065			116,077			34,015			129,001
	Net Income (loss)			1,081			225,499			-11,711			161,636			304,267			-420,689			260,083
	Net Income attributable to noncontrolling interests			-			-			-			-			-			34,584			34,584
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-455,273		$	225,499
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
				For the three months ended March 31, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-286,004		$	247,350
		Gain (loss) related to cash flow hedges			-			7,234			-			-			-275			-			6,959
		Actuarial gain (loss) on defined benefit pension plans			-			50			947			3,262			95			-			4,354
		Gain (loss) related to foreign currency translation			-			833			-145			-			-50,268			2,524			-47,056
		Income tax (expense) benefit related to components of other comprehensive income			-			-2,097			-276			-1,287			110			-			-3,550
	Other comprehensive income (loss), net of tax				-			6,020			526			1,975			-50,338			2,524			-39,293
	Total comprehensive income			$	1,103		$	211,482		$	4,347		$	145,119		$	129,486		$	-283,480		$	208,057
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			41,855			41,855
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	1,103		$	211,482		$	4,347		$	145,119		$	129,486		$	-325,335		$	166,202
				For the three months ended March 31, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-420,689		$	260,083
		Gain (loss) related to cash flow hedges			-			12,864			-			-			3,033			-			15,897
		Actuarial gain (loss) on defined benefit pension plans			-			32			637			5,668			61			-			6,398
		Gain (loss) related to foreign currency translation			-			67,232			-22,010			-			-115,710			2,296			-68,192
		Income tax (expense) benefit related to components of other comprehensive income			-			-3,707			-186			-2,236			-555			-			-6,684
	Other comprehensive income (loss), net of tax				-			76,421			-21,559			3,432			-113,171			2,296			-52,581
	Total comprehensive income			$	1,081		$	301,920		$	-33,270		$	165,068		$	191,096		$	-418,393		$	207,502
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			32,602			32,602
Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	1,081		$	301,920		$	-33,270		$	165,068		$	191,096		$	-450,995		$	174,900
			At March 31, 2014
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	0		$	293		$	5,198		$	-		$	569,325		$	-689		$	574,127
	Trade accounts receivable, less allowance for doubtful accounts			-			-			141,776			-			2,936,792			1,766			3,080,334
	Accounts receivable from related parties			1,251,652			1,082,152			925,520			1,654,727			4,395,927			-9,138,792			171,186
	Inventories			-			-			314,500			-			1,046,933			-154,661			1,206,772
	Prepaid expenses and other current assets			-			47,005			70,159			117			1,041,383			36,728			1,195,392
	Deferred taxes			-			-			-			-			312,758			-43,848			268,910
		Total current assets		1,251,652			1,129,450			1,457,153			1,654,844			10,303,118			-9,299,496			6,496,721
Property, plant and equipment, net				-			679			255,385			-			3,003,849			-124,790			3,135,123
Intangible assets				-			387			71,527			-			662,404			-91			734,227
Goodwill				-			-			62,815			-			11,583,342			-			11,646,157
Deferred taxes				-			83,365			14,762			-			119,945			-109,592			108,480
Other assets and notes receivables(1)				-			14,313,281			48,249			12,851,806			5,211,198			-31,122,565			1,301,969
	Total assets		$	1,251,652		$	15,527,162		$	1,909,891		$	14,506,650		$	30,883,856		$	-40,656,534		$	23,422,677
Current liabilities:
	Accounts payable		$	-		$	726		$	32,836		$	-		$	517,106		$	-		$	550,668
	Accounts payable to related parties			-			2,199,883			665,432			1,571,744			5,126,683			-9,399,513			164,229
	Accrued expenses and other current liabilities			11,833			83,607			143,998			8,948			1,642,610			9,243			1,900,239
	Short-term borrowings			-			56,536			-			-			100,690			-			157,226
	Short-term borrowings from related parties			-			-			-			-			134,314			-			134,314
	Current portion of long-term debt and capital lease obligations			-			78,195			-			200,000			23,080			-			301,275
	Income tax payable			-			123,187			-			-			85,921			-5,554			203,554
	Deferred taxes			-			1,869			10,567			-			66,021			-42,646			35,811
		Total current liabilities		11,833			2,544,003			852,833			1,780,692			7,696,425			-9,438,470			3,447,316
Long term debt and capital lease obligations, less current portion				1,166,233			152,002			-			2,586,469			7,681,126			-3,569,675			8,016,155
Long term borrowings from related parties				-			3,359,322			-			2,092,452			6,491			-5,458,265			-
Other liabilities				-			5,557			5,837			267,855			30,366			23,605			333,220
Pension liabilities				-			11,426			260,023			-			142,892			-953			413,388
Income tax payable				2,915			30,840			-			-			21,549			110,736			166,040
Deferred taxes				-			-			-			-			759,967			-25,638			734,329
		Total liabilities		1,180,981			6,103,150			1,118,693			6,727,468			16,338,816			-18,358,660			13,110,448
Noncontrolling interests subject to put provisions				-			-			0			-			631,940			-			631,940
Total FMC-AG & Co. KGaA shareholders' equity				70,671			9,424,012			791,198			7,779,182			13,656,823			-22,297,874			9,424,012
Noncontrolling interests not subject to put provisions				-			-			-			-			256,277			-			256,277
Total equity				70,671			9,424,012			791,198			7,779,182			13,913,100			-22,297,874			9,680,289
	Total liabilities and equity		$	1,251,652		$	15,527,162		$	1,909,891		$	14,506,650		$	30,883,856		$	-40,656,534		$	23,422,677
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
			At December 31, 2013
			Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
Current assets:
	Cash and cash equivalents		$	0		$	13		$	4,490		$	-		$	672,206		$	6,068		$	682,777
	Trade accounts receivable, less allowance for doubtful accounts			-			-			152,480			-			2,882,736			2,058			3,037,274
	Accounts receivable from related parties			1,269,092			960,137			815,748			1,643,394			4,073,975			-8,609,228			153,118
	Inventories			-			-			287,625			-			946,790			-137,311			1,097,104
	Prepaid expenses and other current assets			-			71,939			41,240			167			879,085			44,960			1,037,391
	Deferred taxes			-			-			-			-			322,337			-43,285			279,052
		Total current assets		1,269,092			1,032,089			1,301,583			1,643,561			9,777,129			-8,736,738			6,286,716
Property, plant and equipment, net				-			734			238,469			-			2,980,268			-127,517			3,091,954
Intangible assets				-			501			73,166			-			684,290			-81			757,876
Goodwill				-			-			62,829			-			11,595,358			-			11,658,187
Deferred taxes				-			80,931			14,209			-			118,306			-109,279			104,167
Other assets and notes receivables (1)				-			13,955,933			47,661			12,583,246			5,234,132			-30,599,966			1,221,006
	Total assets		$	1,269,092		$	15,070,188		$	1,737,917		$	14,226,807		$	30,389,483		$	-39,573,581		$	23,119,906
Current liabilities:
	Accounts payable		$	-		$	2,193		$	28,689		$	-		$	511,715		$	-		$	542,597
	Accounts payable to related parties			-			1,896,712			522,719			1,600,480			4,931,344			-8,827,326			123,929
	Accrued expenses and other current liabilities			29,770			45,897			129,727			9,403			1,786,709			11,027			2,012,533
	Short-term borrowings			-			60			-			-			96,588			-			96,648
	Short-term borrowings from related parties			-			-			-			-			62,342			-			62,342
	Current portion of long-term debt and capital lease obligations			-			271,090			-			200,000			40,280			-			511,370
	Income tax payable			-			114,197			-			-			56,163			-			170,360
	Deferred taxes			-			2,331			9,002			-			64,539			-41,678			34,194
		Total current liabilities		29,770			2,332,480			690,137			1,809,883			7,549,680			-8,857,977			3,553,973
Long term debt and capital lease obligations, less current portion				1,167,466			96,699			-			2,438,189			7,478,944			-3,434,378			7,746,920
Long term borrowings from related parties				-			3,359,606			-			2,092,818			6,940			-5,459,364			-
Other liabilities				-			5,616			6,028			267,914			30,399			19,604			329,561
Pension liabilities				-			10,377			254,233			-			171,248			-			435,858
Income tax payable				2,287			30,846			-			-			20,262			123,538			176,933
Deferred taxes				-			-			-			-			768,156			-24,766			743,390
		Total liabilities		1,199,523			5,835,624			950,398			6,608,804			16,025,629			-17,633,343			12,986,635
Noncontrolling interests subject to put provisions				-			-			0			-			648,251			-			648,251
Total FMC-AG & Co. KGaA shareholders' equity				69,569			9,234,564			787,519			7,618,003			13,465,147			-21,940,238			9,234,564
Noncontrolling interests not subject to put provisions				-			-			-			-			250,456			-			250,456
Total equity				69,569			9,234,564			787,519			7,618,003			13,715,603			-21,940,238			9,485,020
	Total liabilities and equity		$	1,269,092		$	15,070,188		$	1,737,917		$	14,226,807		$	30,389,483		$	-39,573,581		$	23,119,906
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				For the three months ended March 31, 2014
				Issuer			Guarantors
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
Operating Activities:
	Net income (loss)			$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-286,004		$	247,350
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-124,293			-			-154,698			-			278,991			-
		Depreciation and amortization			-			168			13,209			-			162,641			-8,851			167,167
		Change in deferred taxes, net			-			-5,141			1,004			-			6,310			-5,632			-3,459
		(Gain) loss on sale of fixed assets and investments			-			-			-48			-			854			-			806
		(Write Up) write-off loans from related parties			-			54,513			-			-			-			-54,513			-
		Compensation expense related to stock options			-			6,174			-			-			-			-			6,174
		Investments in equity method investees, net			-			43,389			-			-			-10,990			-			32,399
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			10,600			-			-73,804			289			-62,915
		Inventories			-			-			-26,758			-			-104,322			19,432			-111,648
		Prepaid expenses and other current and non-current assets			-			27,932			-28,285			-25,230			5,543			-6,791			-26,831
		Accounts receivable from / payable to related parties			19,214			68,641			126,606			-1,109			-214,030			23,481			22,803
		Accounts payable, accrued expenses and other current and non-current liabilities			-17,938			-1,925			23,947			-455			-183,359			-578			-180,308
		Income tax payable			628			8,954			-			-7,528			36,852			-18,150			20,756
			Net cash provided by (used in) operating activities		3,007			283,874			124,096			-45,876			-194,481			-58,326			112,294
Investing Activities:
	Purchases of property, plant and equipment				-			-			-28,346			-			-179,465			8,180			-199,631
	Proceeds from sale of property, plant and equipment				-			-			128			-			2,352			-			2,480
	Disbursement of loans to related parties				-			-88,773			-			-63,712			-			152,485			-
	Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-63,444			-1,216			-			-136,985			64,488			-137,157
	Proceeds from divestitures				-			-			-			-			2,381			-			2,381
			Net cash provided by (used in) investing activities		-			-152,217			-29,434			-63,712			-311,717			225,153			-331,927
Financing Activities:
	Short-term borrowings, net				-			-60			-93,960			-			171,121			-			77,101
	Long-term debt and capital lease obligations, net				-3,007			-136,960			-			109,588			186,922			-152,485			4,058
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			68,000			-			68,000
	Proceeds from exercise of stock options				-			5,266			-			-			541			-			5,807
	Capital increase (decrease)				-			-			-			-			21,099			-21,099			-
	Distributions to noncontrolling interest				-			-			-			-			-52,157			-			-52,157
	Contributions from noncontrolling interest				-			-			-			-			13,402			-			13,402
			Net cash provided by (used in) financing activities		-3,007			-131,754			-93,960			109,588			408,928			-173,584			116,211
Effect of exchange rate changes on cash and cash equivalents					-			377			6			-			-5,611			-			-5,228
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					0			280			708			-			-102,881			-6,757			-108,650
Cash and cash equivalents at beginning of period					0			13			4,490			-			672,206			6,068			682,777
Cash and cash equivalents at end of period				$	0		$	293		$	5,198		$	-		$	569,325		$	-689		$	574,127
				For the three months ended March 31, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
Operating Activities:
	Net income (loss)			$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-420,689		$	260,083
	Adjustments to reconcile net income to net cash provided by (used in) operating activities:
	Equity affiliate income				-			-117,240			-			-181,689			-			298,929			-
		Depreciation and amortization			-			169			12,184			-			151,774			-7,774			156,353
		Change in deferred taxes, net			-			-14,876			2,705			-			-3,914			-6,370			-22,455
		(Gain) loss on sale of fixed assets and investments			-			-12			-115			-			455			-			328
		Compensation expense related to stock options			-			6,220			-			-			-			-			6,220
		Investments in equity method investees, net			-			22,816			-			-			-4,234			-			18,582
	Changes in assets and liabilities, net of amounts from businesses acquired:
		Trade accounts receivable, net			-			-			-15,829			-			-24,873			-			-40,702
		Inventories			-			-			-12,488			-			-59,019			15,334			-56,173
		Prepaid expenses and other current and non-current assets			-			-19,210			-9,435			-6,047			66,903			-132			32,079
		Accounts receivable from / payable to related parties			8,547			-76,649			52,601			28,490			-80,161			65,697			-1,475
		Accounts payable, accrued expenses and other current and non-current liabilities			-7,273			3,603			19,261			-921			-115,523			1,182			-99,671
		Income tax payable			616			-923			-			-13,065			50,431			25,190			62,249
			Net cash provided by (used in) operating activities		2,971			29,397			37,173			-11,596			286,106			-28,633			315,418
Investing Activities:
	Purchases of property, plant and equipment				-			-14			-13,577			-			-139,502			5,736			-147,357
	Proceeds from sale of property, plant and equipment				-			17			180			-			1,130			-			1,327
	Disbursement of loans to related parties				-			-22,515			-			83,644			-			-61,129			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-23,152			-1,424			-			-69,095			21,457			-72,214
	Proceeds from divestitures				-			-			-			-			-63,452			64,488			1,036
	Net cash provided by (used in) investing activities				-			-45,664			-14,821			83,644			-270,919			30,552			-217,208
Financing Activities:
	Short-term borrowings, net				-			4,226			-22,794			-			25,607			-			7,039
	Long-term debt and capital lease obligations, net				-2,972			-			-			1,659,914			-1,750,388			61,129			-32,317
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			-162,000			-			-162,000
	Proceeds from exercise of stock options				-			4,113			-			-			522			-			4,635
	Capital increase (decrease)				-			-			-			-1,731,962			1,730,603			1,359			-
	Distributions to noncontrolling interest				-			-			-			-			-72,619			-			-72,619
	Contributions from noncontrolling interest				-			-			-			-			8,795			-			8,795
	Net cash provided by (used in) financing activities				-2,972			8,339			-22,794			-72,048			-219,480			62,488			-246,467
Effect of exchange rate changes on cash and cash equivalents					-			8,461			-2			-			-13,401			-			-4,942
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					-1			533			-444			-			-217,694			64,407			-153,199
Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
Cash and cash equivalents at end of period				$	0		$	611		$	57		$	-		$	468,763		$	65,410		$	534,841

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventories (Tables) [Abstract]	'
Inventory Disclosure Tables [Text Block]	'
				31-Mar-14		31-Dec-13
	Finished goods		$	751,027	$	640,355
	Raw materials and purchased components			194,808		185,146
	Health care supplies			186,687		195,519
	Work in process			74,250		76,084
		Inventories	$	1,206,772	$	1,097,104

Longterm_Debt_and_Capital_Leas1

Long-term Debt and Capital Lease Obligations (Tables)	3 Months Ended
	Mar. 31, 2014
Long Term Debt and Capital Lease Obligations (Tables) [Abstract]	'
Schedule of long-term debt	'
			Maximum Amount Available(1)			Balance Outstanding
		31-Mar-14		31-Dec-13		31-Mar-14		31-Dec-13
	Accounts Receivable Facility	$	800,000	$	800,000	$	419,250	$	351,250
	(1) Subject to availability of sufficient accounts receivable meeting funding criteria.
2006 Senior Credit Agreement Table	'
		Maximum Amount Available March 31, 2014				Balance Outstanding March 31, 2014
	Revolving Credit USD	$	600,000	$	600,000	$	336,469	$	336,469
	Revolving Credit EUR	€	500,000	$	689,400	€	90,000	$	124,092
	Term Loan A	$	2,450,000	$	2,450,000	$	2,450,000	$	2,450,000
				$	3,739,400			$	2,910,561
		Maximum Amount Available December 31, 2013				Balance Outstanding December 31, 2013
	Revolving Credit USD	$	600,000	$	600,000	$	138,190	$	138,190
	Revolving Credit EUR	€	500,000	$	689,550	€	50,000	$	68,955
	Term Loan A	$	2,500,000	$	2,500,000	$	2,500,000	$	2,500,000
				$	3,789,550			$	2,707,145

Earning_Per_Share_Tables

Earning Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share (Tables) [Abstract]	'
Schedule of Earning per Share	'
			For the three months ended March 31,
			2014		2013
	Numerators:
	Net income attributable to shareholders of FMC-AG & Co. KGaA		$	205,462	$	225,499
	less:
		Dividend preference on Preference shares(1)		-		26
	Income available to all classes of shares		$	205,462	$	225,473
	Denominators:
	Weighted average number of:
	Ordinary shares outstanding			301,491,046		302,773,218
	Preference shares outstanding(1)			-		3,973,333
	Total weighted average shares outstanding			301,491,046		306,746,551
	Potentially dilutive Ordinary shares			378,831		1,131,149
	Potentially dilutive Preference shares(1)			-		13,681
	Total weighted average Ordinary shares outstanding assuming dilution			301,869,877		303,904,367
	Total weighted average Preference shares outstanding assuming dilution(1)			-		3,987,014
	Basic income per Ordinary share		$	0.68	$	0.74
	Fully diluted income per Ordinary share			0.68		0.73
	(1) As of the preference share conversion on June 28th, 2013, the Company no longer has two classes of shares outstanding.

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2014
Employee Benefit Plans (Tables) [Abstract]	'
Schedule of the components of net periodic benefit cost	'
		For the three months ended March 31,
		2014		2013
	Components of net periodic benefit cost:
	Service cost	$	4,739	$	3,913
	Interest cost		7,404		6,784
	Expected return on plan assets		-3,925		-3,400
	Amortization of unrealized losses		4,354		6,398
	Net periodic benefit costs	$	12,572	$	13,695

Noncontrolling_Interests_Subje1

Noncontrolling Interests Subject To Put Provisions (Tables)	3 Months Ended
	Mar. 31, 2014
Noncontrolling Interests Subject To Put Provisions (Tables) [Abstract]	'
Noncontrolling Interests Subject to Put Provisions	'
	8. Noncontrolling Interests Subject to Put Provisions
	The Company has potential obligations to purchase the noncontrolling interests held by third parties in certain of its consolidated subsidiaries. These obligations are in the form of put provisions and are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. If these put provisions were exercised, the Company would be required to purchase all or part of third-party owners' noncontrolling interests at the appraised fair value at the time of exercise. The methodology the Company uses to estimate the fair values of the noncontrolling interest subject to put provisions assumes the greater of net book value or a multiple of earnings, based on historical earnings, development stage of the underlying business and other factors. The estimated fair values of the noncontrolling interests subject to these put provisions can also fluctuate and the implicit multiple of earnings at which these noncontrolling interest obligations may ultimately be settled could vary significantly from our current estimates depending upon market conditions.
	At March 31, 2014 and December 31, 2013, the Company's potential obligations under these put options were $631,940 and $648,251, respectively, of which, at March 31, 2014, put options with an aggregate purchase obligation of $251,453 were exercisable. No put options were exercised during the first three months of 2014.
	The following is a roll forward of noncontrolling interests subject to put provisions for the three months ended March 31, 2014 and the year ended December 31, 2013:
		31-Mar-14		31-Dec-13
	Beginning balance as of January 1,	$	648,251	$	523,260
	Contributions to noncontrolling interests		-29,121		-122,179
	Purchase/ sale of noncontrolling interests		-4,452		6,723
	Contributions from noncontrolling interests		4,329		17,767
	Changes in fair value of noncontrolling interests		-13,847		108,575
	Net income		26,768		113,156
	Other comprehensive income (loss)		12		949
	Ending balance as of March 31, 2014 and December 31, 2013	$	631,940	$	648,251

Patient_Service_Revenue_Tables

Patient Service Revenue (Tables)	3 Months Ended
	Mar. 31, 2014
Patient Service Revenue by Payor (Abstract)	'
Patient Service Revenue [Text Block]	'
		For the three months ended March 31,
			2014		2013
	Medicare ESRD program	$	1,094,338	$	1,055,056
	Private/alternative payors		947,477		914,397
	Medicaid and other government sources		109,486		91,026
	Hospitals		112,701		106,931
	Total patient service revenue	$	2,264,002	$	2,167,410

Financial_Instrument_Tables

Financial Instrument (Tables)	3 Months Ended
	Mar. 31, 2014
Financial Instruments (Tables) [Abstract]	'
Non-Derivative Financial Instruments	'
						March 31,						December 31,
						2014						2013
			Fair Value			Carrying			Fair			Carrying			Fair
			Hierarchy			Amount			Value			Amount			Value
	Assets
		Cash and cash equivalents	1		$	574,127			574,127		$	682,777			682,777
		Accounts Receivable(1)	2			3,251,520			3,251,520			3,190,392			3,190,392
		Notes Receivable	3			166,631			184,242			165,807			175,768
	Liabilities
		Accounts payable(1)	2			714,897			714,897			666,526			666,526
		Short-term borrowings(1)	2			291,540			291,540			158,990			158,990
		Long term debt, excluding 2012 Credit Agreement, Euro Notes and Senior Notes	2			534,950			534,950			679,847			679,847
		2012 Credit Agreement	2			2,910,561			2,910,561			2,707,145			2,710,270
		Senior Notes	2			4,825,384			5,332,253			4,824,753			5,348,679
		Euro Notes	2			46,535			46,722			46,545			47,423
	Noncontrolling interests subject to put provisions		3			631,940			631,940			648,251			648,251
	(1) Also includes amounts receivable from or payable to related parties.
Derivative Financial Instruments Valuation	'
				31-Mar-14						31-Dec-13
					Assets(2)			Liabilities(2)			Assets(2)			Liabilities(2)
	Derivatives in cash flow hedging relationships (1)
		Current
			Foreign exchange contracts		3,235			-2,856			4,985			-2,719
		Non-current
			Foreign exchange contracts		204			-			759			-374
			Interest rate contracts		-			-4,553			-			-4,392
	Total			$	3,439		$	-7,409		$	5,744		$	-7,485
	Derivatives not designated as hedging instruments (1)
		Current
			Foreign exchange contracts		15,373			-15,449			11,679			-22,982
		Non-current
			Foreign exchange contracts		556			-648			1,060			-820
	Total			$	15,929		$	-16,097		$	12,739		$	-23,802
	(1) At March 31, 2014 and December 31, 2013, the valuation of the Company's derivatives was determined using Significant Other Observable Inputs (Level 2) in accordance with the fair value hierarchy levels established in U.S. GAAP.
	(2) Derivative instruments are marked to market each reporting period resulting in carrying amounts being equal to fair values at the reporting date.
Effect of Derivatives on the Consolidated Financial Statements	'
	The Effect of Derivatives on the Consolidated Financial Statements
				Amount of Gain or (Loss) Recognized in OCI on Derivatives					Location of (Gain) or Loss Reclassified from AOCI in Income				Amount of (Gain) or Loss Reclassified from AOCI in Income
	Derivatives in Cash Flow Hedging Relationships
				(Effective Portion) for the three months ended March 31,										(Effective Portion) for the three months ended March 31,
				2014			2013		(Effective Portion)				2014			2013
	Interest rate contracts		$	-125		$	6,470		Interest income/expense			$	7,358		$	6,365
	Foreign exchange contracts			-845			3,991		Costs of Revenue				571			-1,345
	Foreign exchange contracts								Interest income/expense				-			416
			$	-970		$	10,461					$	7,929		$	5,436
	Derivatives not Designated as Hedging Instruments						Amount of (Gain) or Loss Recognized in Income on Derivatives for the three months ended March 31,
				Location of (Gain) or Loss Recognized in Income on Derivative
							2014			2013
	Foreign exchange contracts			Selling, general and administrative expense		$	-2,298		$	-21,812
	Foreign exchange contracts			Interest income/expense			1,226			1,966
						$	-1,072		$	-19,846

Other_Comprehensive_Income_Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2014
Other Comprehensive Income (Tables) [Abstract]	'
Other Comprehensive Income Rollforward [Text Block]	'
			Gain (Loss) related to cash flow hedges			Actuarial gain (loss) on defined benefit pension plans			Gain (Loss) related to foreign-currency translation		Total, before non-controlling interests		Non-controlling interests		Total
	Balance at December 31, 2012		$	-138,341		$	-179,423		$	-174,349	$	-492,113	$	2,869	$	-489,244
		Other comprehensive income (loss) before reclassifications		8,031			-			-66,210		-58,179		-1,982		-60,161
		Amounts reclassified from AOCI		3,639			3,941			-		7,580		-		7,580
	Other comprehensive income (loss) after reclassifications			11,670			3,941			-66,210		-50,599		-1,982		-52,581
	Balance at March 31, 2013		$	-126,671		$	-175,482		$	-240,559	$	-542,712	$	887	$	-541,825
	Balance at December 31, 2013		$	-121,856		$	-141,987		$	-286,744	$	-550,587	$	825	$	-549,762
		Other comprehensive income (loss) before reclassifications		-556			-			-47,023		-47,579		-33		-47,612
		Amounts reclassified from AOCI		5,579			2,740			-		8,319		-		8,319
	Other comprehensive income (loss) after reclassifications			5,023			2,740			-47,023		-39,260		-33		-39,293
	Balance at March 31, 2014		$	-116,833		$	-139,247		$	-333,767	$	-589,847	$	792	$	-589,055
Other Comprehensive Income Reclassifications [Text Block]	'
	Details about AOCI Components			Amount of (Gain) Loss reclassified from AOCI in Income						Location of (Gain) Loss reclassified from AOCI in Income
				For the three months ended March 31,
				2014			2013
	(Gain) Loss related to cash flow hedges
		Interest rate contracts		$	7,358		$	6,365		Interest income/expense
		Foreign exchange contracts			571			-1,345		Costs of Revenue
		Foreign exchange contracts			-			416		Interest income/expense
					7,929			5,436		Total before tax
					-2,350			-1,797		Tax expense or benefit
				$	5,579		$	3,639		Net of tax
	Actuarial (Gain) Loss on defined benefit pension plans
		Amortization of unrealized (gain) /loss			4,354			6,398		-1
					4,354			6,398		Total before tax
					-1,614			-2,457		Tax expense or benefit
				$	2,740		$	3,941		Net of tax
	Total reclassifications for the period			$	8,319		$	7,580		Net of tax
	(1) Included in the computation of net periodic pension cost (see Note 7 for additional details).

Business_Segment_Information_T

Business Segment Information (Tables)	3 Months Ended
	Mar. 31, 2014
Business Segment Information (Tables) [Abstract]	'
Schedule of segment reporting information by segment	'
					North America Segment		International Segment		Segment Totals		Corporate		Total
	Three months ended March 31, 2014
		Net revenue external customers		$	2,392,907	$	1,160,898	$	3,553,805	$	9,787	$	3,563,592
		Inter - segment revenue			1,280		-		1,280		-1,280		-
		Revenue			2,394,187		1,160,898		3,555,085		8,507		3,563,592
		Depreciation and amortization			-87,649		-45,021		-132,670		-34,497		-167,167
		Operating income			335,562		180,446		516,008		-71,113		444,895
		Income (loss) from equity method investees			10,551		1,971		12,522		-		12,522
		Segment assets			14,860,218		6,267,649		21,127,867		2,294,810		23,422,677
			thereof investments in equity method investees		300,110		433,802		733,912		-		733,912
		Capital expenditures, acquisitions and investments (1)			204,899		64,637		269,536		67,252		336,788
	Three months ended March 31, 2013
		Net revenue external customers		$	2,287,250	$	1,168,652	$	3,455,902	$	8,019	$	3,463,921
		Inter - segment revenue			1,075		-		1,075		-1,075		-
		Revenue			2,288,325		1,168,652		3,456,977		6,944		3,463,921
		Depreciation and amortization(2)			-80,407		-45,900		-126,307		-30,046		-156,353
		Operating income (3)			366,048		191,617		557,665		-64,352		493,313
		Income (loss) from equity method investees(4)			3,118		1,690		4,808		-		4,808
		Segment assets			14,044,466		5,896,442		19,940,908		2,198,755		22,139,663
			thereof investments in equity method investees		239,689		361,738		601,427		-		601,427
		Capital expenditures, acquisitions and investments (5)			112,332		82,702		195,034		24,537		219,571
		(1) International acquisitions exclude $7,569 of non-cash acquisitions for 2014.
		(2) Depreciation in the amount of $895 relating to research and development has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(3) Certain items, in the net aggregate amount of $5,006, relating to research and development, compensation expense and income from equity method investees have been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation as applicable.
		(4) Income (loss) from equity method investees in the amount of $396 has been reclassified between the North America Segment, the International Segment and Corporate to conform to the current year’s presentation.
		(5) International acquisitions exclude $3,690 of non-cash acquisitions for 2013.

Supplementary_Cash_Flow_Inform1

Supplementary Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2014
Supplementary Cash Flow Information (Tables) [Abstract]	'
Schedule of supplemental Cash Flow information	'
			Three months ended March 31,
			2014		2013
	Supplementary cash flow information:
		Cash paid for interest	$	164,393	$	165,596
		Cash paid for income taxes (1)	$	83,138	$	59,708
		Cash inflow for income taxes from stock option exercises	$	545	$	522
	Supplemental disclosures of cash flow information:
		Details for acquisitions:
		Assets acquired	$	-31,589	$	-69,485
		Liabilities assumed		2,251		3,334
		Noncontrolling interest subject to put provisions		-		6,294
		Noncontrolling interest		288		4,527
		Obligations assumed in connection with acquisition		7,569		3,690
		Cash paid		-21,481		-51,640
		Less cash acquired		105		2,530
		Net cash paid for acquisitions		-21,376		-49,110
		Cash paid for investments		-112,848		-22,185
		Cash paid for intangible assets		-2,933		-919
		Total cash paid for acquisitions and investments, net of cash acquired, and purchases of intangible assets	$	-137,157	$	-72,214
		(1) Net of tax refund.

Supplemental_Condensed_Combini1

Supplemental Condensed Combining Information (Tables)	3 Months Ended
	Mar. 31, 2014
Supplemental Condensed Combining Information (Tables) [Abstract]	'
Income statement information segregated by issuers and guarantors	'
			For the three months ended March 31, 2014
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	531,730		$	-		$	3,896,574		$	-864,712		$	3,563,592
	Cost of revenue			-			-			332,156			-			2,995,003			-845,699			2,481,460
		Gross profit		-			-			199,574			-			901,571			-19,013			1,082,132
	Operating expenses (income):
		Selling, general and administrative(1)		-			47,374			28,650			-26,380			569,452			-11,887			607,209
		Research and development		-			-			19,297			-			10,731			-			30,028
	Operating (loss) income			-			-47,374			151,627			26,380			321,388			-7,126			444,895
	Other (income) expense:
		Interest, net		-1,731			60,526			-1,031			45,462			-7,015			50			96,261
		Other, net		-			-330,870			111,665			-154,698			-			373,903			-
	Income (loss) before income taxes			1,731			222,970			40,993			135,616			328,403			-381,079			348,634
		Income tax expense (benefit)		628			17,508			37,172			-7,528			148,579			-95,075			101,284
	Net Income (loss)			1,103			205,462			3,821			143,144			179,824			-286,004			247,350
	Net Income attributable to noncontrolling interests			-			-			-			-			-			41,888			41,888
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-327,892		$	205,462
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
			For the three months ended March 31, 2013
			Issuer			Guarantors
			FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH			Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Net revenue		$	-		$	-		$	495,497		$	-		$	3,758,626		$	-790,202		$	3,463,921
	Cost of revenue			-			-			335,779			-			2,796,879			-778,255			2,354,403
		Gross profit		-			-			159,718			-			961,747			-11,947			1,109,518
	Operating expenses (income):
		Selling, general and administrative (1)		-			6,423			49,086			-7,180			511,647			25,857			585,833
		Research and development		-			-			17,969			-			12,572			-169			30,372
	Operating (loss) income			-			-6,423			92,663			7,180			437,528			-37,635			493,313
	Other (income) expense:
		Interest, net		-1,697			46,193			2,251			40,298			17,184			-			104,229
		Other, net		-			-263,397			96,047			-181,689			-			349,039			-
	Income (loss) before income taxes			1,697			210,781			-5,635			148,571			420,344			-386,674			389,084
		Income tax expense (benefit)		616			-14,718			6,076			-13,065			116,077			34,015			129,001
	Net Income (loss)			1,081			225,499			-11,711			161,636			304,267			-420,689			260,083
	Net Income attributable to noncontrolling interests			-			-			-			-			-			34,584			34,584
	Net income (loss) attributable to shareholders of FMC-AG & Co. KGaA		$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-455,273		$	225,499
	(1) Selling, general and administrative is presented net of Gain on Sale of dialysis clinics and net of income from equity method investees.
Balance sheet information segregated by issuers and guarantors	'
				At March 31, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	0		$	293		$	5,198		$	-		$	569,325		$	-689		$	574,127
		Trade accounts receivable, less allowance for doubtful accounts			-			-			141,776			-			2,936,792			1,766			3,080,334
		Accounts receivable from related parties			1,251,652			1,082,152			925,520			1,654,727			4,395,927			-9,138,792			171,186
		Inventories			-			-			314,500			-			1,046,933			-154,661			1,206,772
		Prepaid expenses and other current assets			-			47,005			70,159			117			1,041,383			36,728			1,195,392
		Deferred taxes			-			-			-			-			312,758			-43,848			268,910
			Total current assets		1,251,652			1,129,450			1,457,153			1,654,844			10,303,118			-9,299,496			6,496,721
	Property, plant and equipment, net				-			679			255,385			-			3,003,849			-124,790			3,135,123
	Intangible assets				-			387			71,527			-			662,404			-91			734,227
	Goodwill				-			-			62,815			-			11,583,342			-			11,646,157
	Deferred taxes				-			83,365			14,762			-			119,945			-109,592			108,480
	Other assets and notes receivables(1)				-			14,313,281			48,249			12,851,806			5,211,198			-31,122,565			1,301,969
		Total assets		$	1,251,652		$	15,527,162		$	1,909,891		$	14,506,650		$	30,883,856		$	-40,656,534		$	23,422,677
	Current liabilities:
		Accounts payable		$	-		$	726		$	32,836		$	-		$	517,106		$	-		$	550,668
		Accounts payable to related parties			-			2,199,883			665,432			1,571,744			5,126,683			-9,399,513			164,229
		Accrued expenses and other current liabilities			11,833			83,607			143,998			8,948			1,642,610			9,243			1,900,239
		Short-term borrowings			-			56,536			-			-			100,690			-			157,226
		Short-term borrowings from related parties			-			-			-			-			134,314			-			134,314
		Current portion of long-term debt and capital lease obligations			-			78,195			-			200,000			23,080			-			301,275
		Income tax payable			-			123,187			-			-			85,921			-5,554			203,554
		Deferred taxes			-			1,869			10,567			-			66,021			-42,646			35,811
			Total current liabilities		11,833			2,544,003			852,833			1,780,692			7,696,425			-9,438,470			3,447,316
	Long term debt and capital lease obligations, less current portion				1,166,233			152,002			-			2,586,469			7,681,126			-3,569,675			8,016,155
	Long term borrowings from related parties				-			3,359,322			-			2,092,452			6,491			-5,458,265			-
	Other liabilities				-			5,557			5,837			267,855			30,366			23,605			333,220
	Pension liabilities				-			11,426			260,023			-			142,892			-953			413,388
	Income tax payable				2,915			30,840			-			-			21,549			110,736			166,040
	Deferred taxes				-			-			-			-			759,967			-25,638			734,329
			Total liabilities		1,180,981			6,103,150			1,118,693			6,727,468			16,338,816			-18,358,660			13,110,448
	Noncontrolling interests subject to put provisions				-			-			0			-			631,940			-			631,940
	Total FMC-AG & Co. KGaA shareholders' equity				70,671			9,424,012			791,198			7,779,182			13,656,823			-22,297,874			9,424,012
	Noncontrolling interests not subject to put provisions				-			-			-			-			256,277			-			256,277
	Total equity				70,671			9,424,012			791,198			7,779,182			13,913,100			-22,297,874			9,680,289
		Total liabilities and equity		$	1,251,652		$	15,527,162		$	1,909,891		$	14,506,650		$	30,883,856		$	-40,656,534		$	23,422,677
	(1) Other Assets and notes receivables are presented net of investment in equity method investees.
				At December 31, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Current assets:
		Cash and cash equivalents		$	0		$	13		$	4,490		$	-		$	672,206		$	6,068		$	682,777
		Trade accounts receivable, less allowance for doubtful accounts			-			-			152,480			-			2,882,736			2,058			3,037,274
		Accounts receivable from related parties			1,269,092			960,137			815,748			1,643,394			4,073,975			-8,609,228			153,118
		Inventories			-			-			287,625			-			946,790			-137,311			1,097,104
		Prepaid expenses and other current assets			-			71,939			41,240			167			879,085			44,960			1,037,391
		Deferred taxes			-			-			-			-			322,337			-43,285			279,052
			Total current assets		1,269,092			1,032,089			1,301,583			1,643,561			9,777,129			-8,736,738			6,286,716
	Property, plant and equipment, net				-			734			238,469			-			2,980,268			-127,517			3,091,954
	Intangible assets				-			501			73,166			-			684,290			-81			757,876
	Goodwill				-			-			62,829			-			11,595,358			-			11,658,187
	Deferred taxes				-			80,931			14,209			-			118,306			-109,279			104,167
	Other assets and notes receivables (1)				-			13,955,933			47,661			12,583,246			5,234,132			-30,599,966			1,221,006
		Total assets		$	1,269,092		$	15,070,188		$	1,737,917		$	14,226,807		$	30,389,483		$	-39,573,581		$	23,119,906
	Current liabilities:
		Accounts payable		$	-		$	2,193		$	28,689		$	-		$	511,715		$	-		$	542,597
		Accounts payable to related parties			-			1,896,712			522,719			1,600,480			4,931,344			-8,827,326			123,929
		Accrued expenses and other current liabilities			29,770			45,897			129,727			9,403			1,786,709			11,027			2,012,533
		Short-term borrowings			-			60			-			-			96,588			-			96,648
		Short-term borrowings from related parties			-			-			-			-			62,342			-			62,342
	Current portion of long-term debt and capital lease obligations			-			271,090			-			200,000			40,280			-			511,370
	Income tax payable			-			114,197			-			-			56,163			-			170,360
	Deferred taxes			-			2,331			9,002			-			64,539			-41,678			34,194
		Total current liabilities		29,770			2,332,480			690,137			1,809,883			7,549,680			-8,857,977			3,553,973
Long term debt and capital lease obligations, less current portion				1,167,466			96,699			-			2,438,189			7,478,944			-3,434,378			7,746,920
Long term borrowings from related parties				-			3,359,606			-			2,092,818			6,940			-5,459,364			-
Other liabilities				-			5,616			6,028			267,914			30,399			19,604			329,561
Pension liabilities				-			10,377			254,233			-			171,248			-			435,858
Income tax payable				2,287			30,846			-			-			20,262			123,538			176,933
Deferred taxes				-			-			-			-			768,156			-24,766			743,390
		Total liabilities		1,199,523			5,835,624			950,398			6,608,804			16,025,629			-17,633,343			12,986,635
Noncontrolling interests subject to put provisions				-			-			0			-			648,251			-			648,251
Total FMC-AG & Co. KGaA shareholders' equity				69,569			9,234,564			787,519			7,618,003			13,465,147			-21,940,238			9,234,564
Noncontrolling interests not subject to put provisions				-			-			-			-			250,456			-			250,456
Total equity				69,569			9,234,564			787,519			7,618,003			13,715,603			-21,940,238			9,485,020
	Total liabilities and equity		$	1,269,092		$	15,070,188		$	1,737,917		$	14,226,807		$	30,389,483		$	-39,573,581		$	23,119,906
(1) Other Assets and notes receivables are presented net of investment in equity method investees.
Statement of cash flows information segregated by issuers and guarantors	'
					For the three months ended March 31, 2014
					Issuer			Guarantors
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH		Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
	Operating Activities:
		Net income (loss)			$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-286,004		$	247,350
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-124,293			-			-154,698			-			278,991			-
			Depreciation and amortization			-			168			13,209			-			162,641			-8,851			167,167
			Change in deferred taxes, net			-			-5,141			1,004			-			6,310			-5,632			-3,459
			(Gain) loss on sale of fixed assets and investments			-			-			-48			-			854			-			806
			(Write Up) write-off loans from related parties			-			54,513			-			-			-			-54,513			-
			Compensation expense related to stock options			-			6,174			-			-			-			-			6,174
			Investments in equity method investees, net			-			43,389			-			-			-10,990			-			32,399
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			10,600			-			-73,804			289			-62,915
			Inventories			-			-			-26,758			-			-104,322			19,432			-111,648
			Prepaid expenses and other current and non-current assets			-			27,932			-28,285			-25,230			5,543			-6,791			-26,831
			Accounts receivable from / payable to related parties			19,214			68,641			126,606			-1,109			-214,030			23,481			22,803
			Accounts payable, accrued expenses and other current and non-current liabilities			-17,938			-1,925			23,947			-455			-183,359			-578			-180,308
			Income tax payable			628			8,954			-			-7,528			36,852			-18,150			20,756
				Net cash provided by (used in) operating activities		3,007			283,874			124,096			-45,876			-194,481			-58,326			112,294
	Investing Activities:
		Purchases of property, plant and equipment				-			-			-28,346			-			-179,465			8,180			-199,631
		Proceeds from sale of property, plant and equipment				-			-			128			-			2,352			-			2,480
		Disbursement of loans to related parties				-			-88,773			-			-63,712			-			152,485			-
		Acquisitions and investments, net of cash acquired, and purchases of intangible assets				-			-63,444			-1,216			-			-136,985			64,488			-137,157
		Proceeds from divestitures				-			-			-			-			2,381			-			2,381
				Net cash provided by (used in) investing activities		-			-152,217			-29,434			-63,712			-311,717			225,153			-331,927
	Financing Activities:
		Short-term borrowings, net				-			-60			-93,960			-			171,121			-			77,101
		Long-term debt and capital lease obligations, net				-3,007			-136,960			-			109,588			186,922			-152,485			4,058
		Increase (decrease) of accounts receivable securitization program				-			-			-			-			68,000			-			68,000
		Proceeds from exercise of stock options				-			5,266			-			-			541			-			5,807
		Capital increase (decrease)				-			-			-			-			21,099			-21,099			-
		Distributions to noncontrolling interest				-			-			-			-			-52,157			-			-52,157
		Contributions from noncontrolling interest				-			-			-			-			13,402			-			13,402
				Net cash provided by (used in) financing activities		-3,007			-131,754			-93,960			109,588			408,928			-173,584			116,211
	Effect of exchange rate changes on cash and cash equivalents					-			377			6			-			-5,611			-			-5,228
	Cash and Cash Equivalents:
	Net increase (decrease) in cash and cash equivalents					0			280			708			-			-102,881			-6,757			-108,650
	Cash and cash equivalents at beginning of period					0			13			4,490			-			672,206			6,068			682,777
	Cash and cash equivalents at end of period				$	0		$	293		$	5,198		$	-		$	569,325		$	-689		$	574,127
					For the three months ended March 31, 2013
					Issuer			Guarantors									Non-Guarantor Subsidiaries
					FMC US Finance			FMC - AG & Co. KGaA			D-GmbH				FMCH						Combining Adjustment				Combined Total
	Operating Activities:
		Net income (loss)			$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-420,689		$	260,083
		Adjustments to reconcile net income to net cash provided by (used in) operating activities:
		Equity affiliate income				-			-117,240			-			-181,689			-			298,929			-
			Depreciation and amortization			-			169			12,184			-			151,774			-7,774			156,353
			Change in deferred taxes, net			-			-14,876			2,705			-			-3,914			-6,370			-22,455
			(Gain) loss on sale of fixed assets and investments			-			-12			-115			-			455			-			328
			Compensation expense related to stock options			-			6,220			-			-			-			-			6,220
			Investments in equity method investees, net			-			22,816			-			-			-4,234			-			18,582
		Changes in assets and liabilities, net of amounts from businesses acquired:
			Trade accounts receivable, net			-			-			-15,829			-			-24,873			-			-40,702
			Inventories			-			-			-12,488			-			-59,019			15,334			-56,173
			Prepaid expenses and other current and non-current assets			-			-19,210			-9,435			-6,047			66,903			-132			32,079
			Accounts receivable from / payable to related parties			8,547			-76,649			52,601			28,490			-80,161			65,697			-1,475
			Accounts payable, accrued expenses and other current and non-current liabilities			-7,273			3,603			19,261			-921			-115,523			1,182			-99,671
			Income tax payable			616			-923			-			-13,065			50,431			25,190			62,249
				Net cash provided by (used in) operating activities		2,971			29,397			37,173			-11,596			286,106			-28,633			315,418
	Investing Activities:
	Purchases of property, plant and equipment				-			-14			-13,577			-			-139,502			5,736			-147,357
	Proceeds from sale of property, plant and equipment				-			17			180			-			1,130			-			1,327
	Disbursement of loans to related parties				-			-22,515			-			83,644			-			-61,129			-
	Acquisitions and investments, net of cash acquired, and net purchases of intangible assets				-			-23,152			-1,424			-			-69,095			21,457			-72,214
	Proceeds from divestitures				-			-			-			-			-63,452			64,488			1,036
	Net cash provided by (used in) investing activities				-			-45,664			-14,821			83,644			-270,919			30,552			-217,208
Financing Activities:
	Short-term borrowings, net				-			4,226			-22,794			-			25,607			-			7,039
	Long-term debt and capital lease obligations, net				-2,972			-			-			1,659,914			-1,750,388			61,129			-32,317
	Increase (decrease) of accounts receivable securitization program				-			-			-			-			-162,000			-			-162,000
	Proceeds from exercise of stock options				-			4,113			-			-			522			-			4,635
	Capital increase (decrease)				-			-			-			-1,731,962			1,730,603			1,359			-
	Distributions to noncontrolling interest				-			-			-			-			-72,619			-			-72,619
	Contributions from noncontrolling interest				-			-			-			-			8,795			-			8,795
	Net cash provided by (used in) financing activities				-2,972			8,339			-22,794			-72,048			-219,480			62,488			-246,467
Effect of exchange rate changes on cash and cash equivalents					-			8,461			-2			-			-13,401			-			-4,942
Cash and Cash Equivalents:
Net increase (decrease) in cash and cash equivalents					-1			533			-444			-			-217,694			64,407			-153,199
Cash and cash equivalents at beginning of period					1			78			501			-			686,457			1,003			688,040
Cash and cash equivalents at end of period				$	0		$	611		$	57		$	-		$	468,763		$	65,410		$	534,841
Other comprehensive income statement segregated by issuers and guarantors	'
				For the three months ended March 31, 2014
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	1,103		$	205,462		$	3,821		$	143,144		$	179,824		$	-286,004		$	247,350
		Gain (loss) related to cash flow hedges			-			7,234			-			-			-275			-			6,959
		Actuarial gain (loss) on defined benefit pension plans			-			50			947			3,262			95			-			4,354
		Gain (loss) related to foreign currency translation			-			833			-145			-			-50,268			2,524			-47,056
		Income tax (expense) benefit related to components of other comprehensive income			-			-2,097			-276			-1,287			110			-			-3,550
	Other comprehensive income (loss), net of tax				-			6,020			526			1,975			-50,338			2,524			-39,293
	Total comprehensive income			$	1,103		$	211,482		$	4,347		$	145,119		$	129,486		$	-283,480		$	208,057
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			41,855			41,855
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	1,103		$	211,482		$	4,347		$	145,119		$	129,486		$	-325,335		$	166,202
				For the three months ended March 31, 2013
				Issuer			Guarantors									Non-Guarantor Subsidiaries			Combining Adjustment			Combined Total
				FMC US Finance			FMC - AG & Co. KGaA			D-GmbH			FMCH
	Net Income			$	1,081		$	225,499		$	-11,711		$	161,636		$	304,267		$	-420,689		$	260,083
		Gain (loss) related to cash flow hedges			-			12,864			-			-			3,033			-			15,897
		Actuarial gain (loss) on defined benefit pension plans			-			32			637			5,668			61			-			6,398
		Gain (loss) related to foreign currency translation			-			67,232			-22,010			-			-115,710			2,296			-68,192
		Income tax (expense) benefit related to components of other comprehensive income			-			-3,707			-186			-2,236			-555			-			-6,684
	Other comprehensive income (loss), net of tax				-			76,421			-21,559			3,432			-113,171			2,296			-52,581
	Total comprehensive income			$	1,081		$	301,920		$	-33,270		$	165,068		$	191,096		$	-418,393		$	207,502
		Comprehensive income attributable to noncontrolling interests			-			-			-			-			-			32,602			32,602
	Comprehensive income attributable to shareholders of FMC-AG & Co. KGaA			$	1,081		$	301,920		$	-33,270		$	165,068		$	191,096		$	-450,995		$	174,900

Related_Party_Transactions_Det

Related Party Transactions (Details)

3 Months Ended

3 Months Ended

In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

USD ($)

USD ($)

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

Fresenius SE [Member]

General Partner [Member]

General Partner [Member]

General Partner [Member]

General Partner [Member]

APP Inc [Member]

APP Inc [Member]

Equity Method Investees [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

Fresenius SE Subsidiary [Member]

General partner extensions [Member]

USD ($)

EUR (€)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Services Provided To Related Party [Member]

Services Provided To Related Party [Member]

Operating Lease Agreements [Member]

Operating Lease Agreements [Member]

Sales To Related Party [Member]

Sales To Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

Taxes Receivable [Member]

Taxes Receivable [Member]

USD ($)

EUR (€)

Services Provided By Related Party [Member]

Services Provided By Related Party [Member]

Purchases From Related Party [Member]

Purchases From Related Party [Member]

Sales To Related Party [Member]

USD ($)

Senior notes held by related party [Member]

Senior notes held by related party [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

EUR (€)

Related Party Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

FSE ownership percentage

31.38%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of transaction

'

'

'

'

$27,467

$23,973

$1,848

$1,719

$7,038

$6,569

$7,481

$7,215

$5,907

$10,364

'

'

'

'

$8,172

$4,511

$5,348

$4,560

$655

'

$16,270

€ 11,800

'

Due to related parties

$164,229

$123,929

$72,663

€ 52,700

'

'

'

'

'

'

'

'

'

'

'

'

$2,068

€ 1,500

'

'

'

'

'

$57,515

'

'

'

Interest rate

'

'

1.61%

1.61%

'

'

'

'

'

'

'

'

'

'

'

'

1.34%

1.34%

'

'

'

'

'

6.10%

5.25%

5.25%

1.88%

Date of repayment

'

'

30-Apr-14

30-Apr-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23-May-14

'

'

'

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories (Details) [Abstract]	'	'
Raw materials and purchased components	$194,808	$185,146
Work in process	74,250	76,084
Finished goods	751,027	640,355
Health care supplies	186,687	195,519
Inventories	$1,206,772	$1,097,104

Other_Assets_and_Notes_Receiva

Other Assets and Notes Receivable (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Accounts notes and loans receivable [LineItems]	'
Borrowings Available Under Notes Receivable	200,000
Notes Receivable Maturity Date	'date of July 4, 2020 (unless prepaid)
Notes Receivable Cash Interest Rate	10.75%
Notes Receivable PIK Interest Rate	11.75%
Notes Receivable Balance	$170,000
Notes Receivable Net Payment	165,542
Notes Receivable Interest Income	$2,538

Longterm_Debt_and_Capital_Leas2

Long-term Debt and Capital Lease Obligations (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	$4,825,384	$4,824,753
Capital lease obligations	24,875	24,264
Other	90,825	111,259
Long-term debt and capital lease obligations	8,317,430	8,258,290
Less current maturities	301,275	511,370
Total long-term debt less current maturities	8,016,155	7,746,920
Revolving credit maximum amount available	3,739,400	3,789,550
Revolving credit balance outstanding	2,910,561	2,707,145
Accounts receivable facility	419,250	351,250
Senior Credit Agreement 2012 Member [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Credit Agreement	2,910,561	2,707,145
Line of credit outstanding which reduces available borrowings under the revolving credit facility	7,143	9,444
RevolvingCreditUSD [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	600,000	600,000
Revolving credit balance outstanding	336,469	138,190
RevolvingCreditEUR [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	689,400	689,550
Revolving credit balance outstanding	124,092	68,955
TermLoanA2012 [Member]	'	'
Debt Instrument [Line Items]	'	'
Revolving credit maximum amount available	2,450,000	2,500,000
Revolving credit balance outstanding	2,450,000	2,500,000
Euro Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	46,535	46,545
EIB Agreements [Member]	'	'
Debt Instrument [Line Items]	'	'
Senior Long Term Notes	'	193,074
Accounts Receivable Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Maximum amount available	800,000	'
Balance outstanding	351,250	'
Line of credit outstanding which reduces available borrowings under the revolving credit facility	$65,622	'

Recovered_Sheet1

Short-term Borrowings and Other Financial Liabilities and Short-term Borrowings from Related Parties (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
In Thousands, unless otherwise specified			Fresenius SE [Member]	General Partner [Member]
Short Term Borrowings Other Financial Liabilities And Short Term Borrowings From Related Parties (Details) [Abstract]	'	'	'	'
Borrowings under lines of credit	$100,429	$95,690	'	'
Accounts receivable facility	419,250	351,250	'	'
Other financial liabilities	56,797	958	'	'
Related Party Transaction [Line Items]	'	'	'	'
Related Party Transaction Rate	'	'	1.61%	1.34%
Short-term borrowings and other financial liabilities	157,226	96,648	'	'
Short Term Borrowings Due To Related Parties Current Acquisitions	134,314	62,342	'	'
Short-term borrowings, Other financial liabilities and Short-term borrowings from related parties	$291,540	$158,990	'	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Numerators:	'	'
Income attributable to the Company	$205,462,000	$225,499,000
Less: Dividend preference on Preference shares	'	26,000
Income available to all classes of shares	205,462,000	225,473,000
Denominators:	'	'
Weighted average number of ordinary shares outstanding	301,491,046	302,773,218
Weighted average number of preference shares outstanding	0	3,973,333
Total weighted average shares outstanding	301,491,046	306,746,551
Potentially dilutive Ordinary shares	378,831	1,131,149
Potentially dilutive Preference shares	0	13,681
Total weighted average Ordinary shares outstanding assuming dilution	301,869,877	303,904,367
Total weighted average Preference shares outstanding assuming dilution	0	3,987,014
Basic income per Ordinary share	$0.68	$0.74
Fully diluted income per Ordinary share	$0.68	$0.73

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Components Of Net Periodic Benefit Cost [Abstract]	'	'
Service cost	$4,739	$3,913
Interest cost	7,404	6,784
Expected return on plan assets	-3,925	-3,400
Amortization of unrealized losses	4,354	6,398
Net periodic benefit costs	$12,572	$13,695

Noncontrolling_Interests_Subje2

Noncontrolling Interests Subject to Put Provisions (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Noncontrolling Interests Subject To Put Provisions (Details) [Abstract]	'	'	'
Potential obligations under the put provisions	$631,940	'	$648,251
Temporary Equity [Line Items]	'	'	'
Noncontrolling interests subject to put provisions beginning balance	648,251	'	'
Dividends paid	'	'	296,134
Minority interest increase from stock issuance	-2,879	'	-15,173
Minority interest decrease from distributions to noncontrolling interest holders	-8,951	'	-32,275
Changes in fair value of noncontrolling interests	13,847	'	-108,575
Net Income	247,350	260,083	'
Other comprehensive income loss net of tax	-39,293	-52,581	'
Noncontrolling interests subject to put provisions ending balance	631,940	'	648,251
Put provisions exercisable	251,453	'	'
Noncontrolling interests subject to put provisions [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Noncontrolling interests subject to put provisions beginning balance	523,260	'	'
Dividends paid	-29,121	'	-122,179
Minority interest increase from stock issuance	-4,452	'	6,723
Minority interest decrease from distributions to noncontrolling interest holders	4,329	'	17,767
Changes in fair value of noncontrolling interests	-13,847	'	108,575
Net Income	26,768	'	113,156
Other comprehensive income loss net of tax	12	'	949
Noncontrolling interests subject to put provisions ending balance	'	'	$523,260

Patient_Service_Revenue_Detail

Patient Service Revenue (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
In Thousands, unless otherwise specified
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$2,264,002	$2,167,410
Medicare ESRD program	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	1,094,338	1,055,056
Hospitals	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	112,701	106,931
Private	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	947,477	914,397
Medicaid and other government sources	'	'
Patient Service Revenue By Payor [Line Items]	'	'
Patient Service Revenue by Payor	$109,486	$91,026

Financial_Instruments_Details

Financial Instruments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Assets:	'	'	'
Cash and cash equivalents	$574,127	$682,777	$688,040
Liabilities:	'	'	'
Short-term borrowings	157,226	96,648	'
Short-term borrowings from related parties	134,314	62,342	'
Senior Long Term Notes	4,825,384	4,824,753	'
Noncontrolling interests subject to put provisions	631,940	648,251	'
Notional amount of foreign currency cash flow hedge derivatives	174,918	238,983	'
Notional amount of interest rate derivatives	1,685,750	1,512,559	'
Amount estimated to be transferred in the future from accumulated OCI into earnings	372	'	'
The time period estimated for the anticipated transfer of interest expense into earnings	'12 months	'	'
Derivative assets subject to master netting agreements	19,048	18,334	'
Derivative liabilities subject to master netting agreements	14,044	16,371	'
Derivative net assets subject to master netting agreements	11,996	12,169	'
Derivative net liabiltiies subject to master netting agreements	6,992	10,207	'
Euro Notes [Member]	'	'	'
Liabilities:	'	'	'
Senior Long Term Notes	46,535	46,545	'
Carrying Reported Amount Fair Value Disclosure [Member]	'	'	'
Assets:	'	'	'
Cash and cash equivalents	574,127	682,777	'
Accounts receivable	3,251,520	3,190,392	'
Long-term notes receivable	166,631	165,807	'
Liabilities:	'	'	'
Accounts Payable	714,897	666,526	'
Short-term borrowings	291,540	158,990	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	534,950	679,847	'
Senior Credit Agreement	2,910,561	2,707,145	'
Carrying Reported Amount Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'
Liabilities:	'	'	'
Senior Long Term Notes	46,535	46,545	'
Carrying Reported Amount Fair Value Disclosure [Member] | Senior Notes [Member]	'	'	'
Liabilities:	'	'	'
Senior Long Term Notes	4,825,384	4,824,753	'
Portion At Fair Value Fair Value Disclosure [Member]	'	'	'
Assets:	'	'	'
Cash and cash equivalents	574,127	682,777	'
Accounts receivable	3,251,520	3,190,392	'
Long-term notes receivable	184,242	175,768	'
Liabilities:	'	'	'
Accounts Payable	714,897	666,526	'
Short-term borrowings	291,540	158,990	'
Long term debt, excluding Amended 2006 Senior Credit Agreement, Euro Notes and Senior Notes	534,950	679,847	'
Senior Credit Agreement	2,910,561	2,710,270	'
Portion At Fair Value Fair Value Disclosure [Member] | Euro Notes [Member]	'	'	'
Liabilities:	'	'	'
Senior Long Term Notes	46,722	47,423	'
Portion At Fair Value Fair Value Disclosure [Member] | Senior Notes [Member]	'	'	'
Liabilities:	'	'	'
Senior Long Term Notes	$5,332,253	$5,348,679	'

Financial_Instruments_Details_

Financial Instruments (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	$3,439	$5,744
Liabilities	-7,409	-7,485
Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	15,929	12,739
Liabilities	-16,097	-23,802
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member]	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	0	'
Foreign Exchange Contract Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	3,235	4,985
Liabilities	-2,856	-2,719
Foreign Exchange Contract Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	15,373	11,679
Liabilities	-15,449	-22,982
Foreign Exchange Contract Non Current [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	204	759
Liabilities	'	-374
Foreign Exchange Contract Non Current [Member] | Nondesignated as Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Assets	556	1,060
Liabilities	-648	-820
Interest Rate Contract Non Current Dollar [Member] | Designated As Hedging Instrument [Member] | Significant Observable Inputs (Level 2)	'	'
Derivatives Fair Value [Line Items]	'	'
Liabilities	($4,553)	($4,392)

Financial_Instruments_Details_1

Financial Instruments (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Designated As Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	($970)	$10,461
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	7,929	5,436
Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	-125	6,470
Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivatives (Effective Portion)	-845	3,991
Nondesignated as Hedging Instrument [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	-1,072	-19,846
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Interest Rate Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	7,358	6,365
Interest Income Expense [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	0	416
Interest Income Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	1,226	1,966
Cost Of Sale [Member] | Designated As Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives AOCI	571	-1,345
Selling, General and Administrative Expense [Member] | Nondesignated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]	'	'
Derivative Instruments Gain Loss [Line Items]	'	'
Amount of (Gain) or Loss Recognized in Income on Derivatives	($2,298)	($21,812)

Other_Comprehensive_Income_Rol

Other Comprehensive Income - Rollforward (Details) (USD $)	3 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Balance	'	'	($549,762)	($489,244)
Other comprehensive income (loss) before reclassifications	-47,612	-60,161	'	'
AOCI reclassifications	8,319	7,580	'	'
Other comprehensive income loss net of taxes	-39,293	-52,581	'	'
Ending Balance OCI	-589,055	-541,825	'	'
Accumulated Net Gain Loss From Designated Or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Balance	'	'	-121,856	-138,341
Other comprehensive income (loss) before reclassifications	-556	8,031	'	'
AOCI reclassifications	5,579	3,639	'	'
Other comprehensive income loss net of taxes	5,023	11,670	'	'
Ending Balance OCI	-116,833	-126,671	'	'
Accumulate benefit plans adjustment [Member]	'	'	'	'
Balance	'	'	-141,987	-179,423
AOCI reclassifications	2,740	3,941	'	'
Other comprehensive income loss net of taxes	2,740	3,941	'	'
Ending Balance OCI	-139,247	-175,482	'	'
Accumulated translation adjustments (Domain) [Member]	'	'	'	'
Balance	'	'	-286,744	-174,349
Other comprehensive income (loss) before reclassifications	-47,023	-66,210	'	'
Other comprehensive income loss net of taxes	-47,023	-66,210	'	'
Ending Balance OCI	-333,767	-240,559	'	'
Total, before non-controlling interests	'	'	'	'
Balance	'	'	-550,587	-492,113
Other comprehensive income (loss) before reclassifications	-47,579	-58,179	'	'
AOCI reclassifications	8,319	7,580	'	'
Other comprehensive income loss net of taxes	-39,260	-50,599	'	'
Ending Balance OCI	-589,847	-542,712	'	'
Noncontrolling interests not subject to put provisions [Member]	'	'	'	'
Balance	'	'	825	2,869
Other comprehensive income (loss) before reclassifications	-33	-1,982	'	'
Other comprehensive income loss net of taxes	-33	-1,982	'	'
Ending Balance OCI	$792	$887	'	'

Other_Comprehensive_Income_Rec

Other Comprehensive Income - Reclassifications (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Other comprehensive income derivatives qualifying as hedges net of tax period increase decrease abstract	'	'
Interest rate contracts	$7,358	$6,365
Foreign exchange contracts cost of revenue	571	-1,345
Foreign exchange contracts interest	0	416
Total before tax	7,929	5,436
Tax expense or benefit	-2,350	-1,797
Net of tax	5,579	3,639
Other comprehensive income defined benefit plans adjustment net of tax period increase decrease abstract	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,354	6,398
Total before tax	4,354	6,398
Benefit plans tax expense	-1,614	-2,457
Benefit plans net of tax	2,740	3,941
Total reclassifications for the period	$8,319	$7,580

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'
Net revenue from external customers	$3,563,592	$3,463,921	'
Segment depreciation and amortization	-167,167	-156,353	'
Operating income	444,895	493,313	'
Income from equity method investees	12,522	4,808	'
Segment assets	23,422,677	'	23,119,906
thereof investment in equity method investees	733,912	'	664,446
Capital expenditures, acquisitions and investments	336,788	219,571	'
Segment Total [Member]	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'
Net revenue from external customers	3,553,805	3,455,902	'
Inter - segment revenue	1,280	1,075	'
Segment revenue	3,555,085	3,456,977	'
Segment depreciation and amortization	-132,670	-126,307	'
Operating income	516,008	557,665	'
Income from equity method investees	12,522	4,808	'
Capital expenditures, acquisitions and investments	269,536	195,034	'
North America [Member]	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'
Net revenue from external customers	2,392,907	2,287,250	'
Inter - segment revenue	1,280	1,075	'
Segment revenue	2,394,187	2,288,325	'
Segment depreciation and amortization	-87,649	-80,407	'
Operating income	335,562	366,048	'
Income from equity method investees	10,551	3,118	'
Capital expenditures, acquisitions and investments	204,899	112,332	'
Exclusion of non-cash acquisitions	6,000	'	'
International [Member]	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'
Net revenue from external customers	1,160,898	1,168,652	'
Segment revenue	1,160,898	1,168,652	'
Segment depreciation and amortization	-45,021	-45,900	'
Operating income	180,446	191,617	'
Income from equity method investees	1,971	1,690	'
Capital expenditures, acquisitions and investments	64,637	82,702	'
Exclusion of non-cash acquisitions	1,731	8,884	'
Corporate1 [Member]	'	'	'
Entity-Wide Information, Revenue from External Customer [Line Items]	'	'	'
Net revenue from external customers	9,787	8,019	'
Inter - segment revenue	-1,280	-1,075	'
Segment revenue	8,507	6,944	'
Segment depreciation and amortization	-34,497	-30,046	'
Operating income	-71,113	-64,352	'
Income from equity method investees	0	0	'
Capital expenditures, acquisitions and investments	67,252	24,537	'
Exclusion of non-cash acquisitions	'	$2,125	'

Supplemental_Condensed_Combini2

Supplemental Condensed Combining Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Consolidated Statements of Income	'	'	'	'
Net revenue	$3,563,592	$3,463,921	'	'
Cost of revenues	2,481,460	2,354,403	'	'
Gross profit	1,082,132	1,109,518	'	'
Research and development	30,028	30,372	'	'
Operating income	444,895	493,313	'	'
Other (income) expense:	'	'	'	'
Gain on the sale of dialysis clinics	2	1,073	'	'
Income before income taxes	348,634	389,084	'	'
Income tax expense	101,284	129,001	'	'
Net Income	247,350	260,083	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	6,959	15,897	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,354	6,398	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-47,056	-68,192	'	'
Other comprehensive income loss tax	-3,550	-6,684	'	'
Less: Net income attributable to noncontrolling interests	41,888	34,584	'	'
Income attributable to the Company	205,462	225,499	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	574,127	'	682,777	688,040
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	3,080,334	'	3,037,274	'
Accounts receivable from related parties	171,186	'	153,118	'
Inventories	1,206,772	'	1,097,104	'
Prepaid expenses and other current assets	1,195,392	'	1,037,391	'
Deferred tax asset, current	268,910	'	279,052	'
Total current assets	6,496,721	'	6,286,716	'
Property, plant and equipment, net	3,135,123	'	3,091,954	'
Intangible assets	734,227	'	757,876	'
Goodwill	11,646,157	'	11,658,187	'
Deferred tax asset, non-current	108,480	'	104,167	'
Total assets	23,422,677	'	23,119,906	'
Current liabilities:	'	'	'	'
Accounts payable	550,668	'	542,597	'
Accounts payable to related parties	164,229	'	123,929	'
Accrued expenses and other current liabilities	1,900,239	'	2,012,533	'
Short-term borrowings and other financial liabilities	157,226	'	96,648	'
Short Term Borrowings Due To Related Parties Current Acquisitions	134,314	'	62,342	'
Current portion of long-term debt and capital lease obligations	301,275	'	511,370	'
Income tax payable, current	203,554	'	170,360	'
Deferred tax liability, current	35,811	'	34,194	'
Total current liabilities	3,447,316	'	3,553,973	'
Total long-term debt less current maturities	8,016,155	'	7,746,920	'
Other liabilities	333,220	'	329,561	'
Pension liabilities	413,388	'	435,858	'
Income tax payable, non-current	166,040	'	176,933	'
Deferred tax liability, non-current	734,329	'	743,390	'
Total liabilities	13,110,448	'	12,986,635	'
Noncontrolling interests subject to put provisions	631,940	'	648,251	'
Company shareholders' equity	9,424,012	'	9,234,564	'
Minority interest	256,277	'	250,456	'
Total equity	9,680,289	'	9,485,020	'
Total liabilities and equity	23,422,677	'	23,119,906	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	247,350	260,083	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	6,959	15,897	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	4,354	6,398	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-47,056	-68,192	'	'
Other comprehensive income loss tax	-3,550	-6,684	'	'
Other comprehensive income (loss), net of tax	-39,293	-52,581	'	'
Total comprehensive income	208,057	207,502	'	'
Comprehensive income attributable to noncontrolling interests	-41,855	-32,602	'	'
Comprehensive income attributable to the Company	166,202	174,900	'	'
Issuers [Member] | FMC US Finance [Member]	'	'	'	'
Other (income) expense:	'	'	'	'
Interest, net	'	-1,697	'	'
Income before income taxes	1,731	1,697	'	'
Income tax expense	628	616	'	'
Net Income	1,103	1,081	'	'
Income attributable to the Company	1,103	1,081	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	0	0	'	1
Accounts receivable from related parties	1,251,652	'	1,269,092	'
Total current assets	1,251,652	'	1,269,092	'
Total assets	1,251,652	'	1,269,092	'
Current liabilities:	'	'	'	'
Accrued expenses and other current liabilities	11,833	'	29,770	'
Total current liabilities	11,833	'	29,770	'
Total long-term debt less current maturities	1,166,233	'	1,167,466	'
Income tax payable, non-current	2,915	'	2,287	'
Total liabilities	1,180,981	'	1,199,523	'
Noncontrolling interests subject to put provisions	70,671	'	'	'
Company shareholders' equity	'	'	69,569	'
Total equity	70,671	'	69,569	'
Total liabilities and equity	1,251,652	'	1,269,092	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	1,103	1,081	'	'
Total comprehensive income	1,103	1,081	'	'
Comprehensive income attributable to the Company	1,103	1,081	'	'
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'	'	'
Consolidated Statements of Income	'	'	'	'
Selling, general and administrative	47,374	6,423	'	'
Operating income	-47,374	-6,423	'	'
Other (income) expense:	'	'	'	'
Interest, net	60,526	46,193	'	'
Other, net	-330,870	-263,397	'	'
Income before income taxes	222,970	210,781	'	'
Income tax expense	17,508	-14,718	'	'
Net Income	205,462	225,499	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	7,234	12,864	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	50	32	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	833	67,232	'	'
Other comprehensive income loss tax	-2,097	-3,707	'	'
Income attributable to the Company	205,462	225,499	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	293	611	13	78
Accounts receivable from related parties	1,082,152	'	960,137	'
Prepaid expenses and other current assets	47,005	'	71,939	'
Total current assets	1,129,450	'	1,032,089	'
Property, plant and equipment, net	679	'	734	'
Intangible assets	387	'	501	'
Deferred tax asset, non-current	83,365	'	80,931	'
Other assets	14,313,281	'	13,955,933	'
Total assets	15,527,162	'	15,070,188	'
Current liabilities:	'	'	'	'
Accounts payable	726	'	2,193	'
Accounts payable to related parties	2,199,883	'	1,896,712	'
Accrued expenses and other current liabilities	83,607	'	45,897	'
Short-term borrowings and other financial liabilities	56,536	'	60	'
Current portion of long-term debt and capital lease obligations	78,195	'	271,090	'
Income tax payable, current	123,187	'	114,197	'
Deferred tax liability, current	1,869	'	2,331	'
Total current liabilities	2,544,003	'	2,332,480	'
Total long-term debt less current maturities	152,002	'	96,699	'
Long term borrowings from related parties	3,359,322	'	3,359,606	'
Other liabilities	5,557	'	5,616	'
Pension liabilities	11,426	'	10,377	'
Income tax payable, non-current	30,840	'	30,846	'
Total liabilities	6,103,150	'	5,835,624	'
Noncontrolling interests subject to put provisions	9,424,012	'	'	'
Company shareholders' equity	'	'	9,234,564	'
Total equity	9,424,012	'	9,234,564	'
Total liabilities and equity	15,527,162	'	15,070,188	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	205,462	225,499	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	7,234	12,864	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	50	32	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	833	67,232	'	'
Other comprehensive income loss tax	-2,097	-3,707	'	'
Other comprehensive income (loss), net of tax	6,020	76,421	'	'
Total comprehensive income	211,482	301,920	'	'
Comprehensive income attributable to the Company	211,482	301,920	'	'
Guarantors [Member] | D GmbH [Member]	'	'	'	'
Consolidated Statements of Income	'	'	'	'
Net revenue	531,730	495,497	'	'
Cost of revenues	332,156	335,779	'	'
Gross profit	199,574	159,718	'	'
Selling, general and administrative	28,650	49,086	'	'
Research and development	19,297	17,969	'	'
Operating income	151,627	92,663	'	'
Other (income) expense:	'	'	'	'
Interest, net	-1,031	2,251	'	'
Other, net	111,665	96,047	'	'
Income before income taxes	40,993	-5,635	'	'
Income tax expense	37,172	6,076	'	'
Net Income	3,821	-11,711	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	947	637	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-145	-22,010	'	'
Other comprehensive income loss tax	-276	-186	'	'
Income attributable to the Company	3,821	-11,711	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	5,198	57	4,490	501
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	141,776	'	152,480	'
Accounts receivable from related parties	925,520	'	815,748	'
Inventories	314,500	'	287,625	'
Prepaid expenses and other current assets	70,159	'	41,240	'
Total current assets	1,457,153	'	1,301,583	'
Property, plant and equipment, net	255,385	'	238,469	'
Intangible assets	71,527	'	73,166	'
Goodwill	62,815	'	62,829	'
Deferred tax asset, non-current	14,762	'	14,209	'
Other assets	48,249	'	47,661	'
Total assets	1,909,891	'	1,737,917	'
Current liabilities:	'	'	'	'
Accounts payable	32,836	'	28,689	'
Accounts payable to related parties	665,432	'	522,719	'
Accrued expenses and other current liabilities	143,998	'	129,727	'
Deferred tax liability, current	10,567	'	9,002	'
Total current liabilities	852,833	'	690,137	'
Other liabilities	5,837	'	6,028	'
Pension liabilities	260,023	'	254,233	'
Total liabilities	1,118,693	'	950,398	'
Company shareholders' equity	791,198	'	787,519	'
Total equity	791,198	'	787,519	'
Total liabilities and equity	1,909,891	'	1,737,917	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	3,821	-11,711	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	947	637	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-145	-22,010	'	'
Other comprehensive income loss tax	-276	-186	'	'
Other comprehensive income (loss), net of tax	526	-21,559	'	'
Total comprehensive income	4,347	-33,270	'	'
Comprehensive income attributable to the Company	4,347	-33,270	'	'
Guarantors [Member] | FMCH [Member]	'	'	'	'
Consolidated Statements of Income	'	'	'	'
Selling, general and administrative	-26,380	-7,180	'	'
Operating income	26,380	7,180	'	'
Other (income) expense:	'	'	'	'
Interest, net	45,462	40,298	'	'
Other, net	-154,698	-181,689	'	'
Income before income taxes	135,616	148,571	'	'
Income tax expense	-7,528	-13,065	'	'
Net Income	143,144	161,636	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	3,262	5,668	'	'
Other comprehensive income loss tax	-1,287	-2,236	'	'
Income attributable to the Company	143,144	161,636	'	'
Current assets:	'	'	'	'
Accounts receivable from related parties	1,654,727	'	1,643,394	'
Prepaid expenses and other current assets	117	'	167	'
Total current assets	1,654,844	'	1,643,561	'
Other assets	12,851,806	'	12,583,246	'
Total assets	14,506,650	'	14,226,807	'
Current liabilities:	'	'	'	'
Accounts payable to related parties	1,571,744	'	1,600,480	'
Accrued expenses and other current liabilities	8,948	'	9,403	'
Current portion of long-term debt and capital lease obligations	200,000	'	200,000	'
Total current liabilities	1,780,692	'	1,809,883	'
Total long-term debt less current maturities	2,586,469	'	2,438,189	'
Long term borrowings from related parties	2,092,452	'	2,092,818	'
Other liabilities	267,855	'	267,914	'
Total liabilities	6,727,468	'	6,608,804	'
Company shareholders' equity	7,779,182	'	7,618,003	'
Total equity	7,779,182	'	7,618,003	'
Total liabilities and equity	14,506,650	'	14,226,807	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	143,144	161,636	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	3,262	5,668	'	'
Other comprehensive income loss tax	-1,287	-2,236	'	'
Other comprehensive income (loss), net of tax	1,975	3,432	'	'
Total comprehensive income	145,119	165,068	'	'
Comprehensive income attributable to the Company	145,119	165,068	'	'
Non Guarantor Subsidiaries [Member]	'	'	'	'
Consolidated Statements of Income	'	'	'	'
Net revenue	3,896,574	3,758,626	'	'
Cost of revenues	2,995,003	2,796,879	'	'
Gross profit	901,571	961,747	'	'
Selling, general and administrative	569,452	511,647	'	'
Research and development	10,731	12,572	'	'
Operating income	321,388	437,528	'	'
Other (income) expense:	'	'	'	'
Interest, net	-7,015	17,184	'	'
Income before income taxes	328,403	420,344	'	'
Income tax expense	148,579	116,077	'	'
Net Income	179,824	304,267	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	-275	3,033	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	95	61	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-50,268	-115,710	'	'
Other comprehensive income loss tax	110	-555	'	'
Income attributable to the Company	179,824	304,267	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	569,325	468,763	672,206	686,457
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	2,936,792	'	2,882,736	'
Accounts receivable from related parties	4,395,927	'	4,073,975	'
Inventories	1,046,933	'	946,790	'
Prepaid expenses and other current assets	1,041,383	'	879,085	'
Deferred tax asset, current	312,758	'	322,337	'
Total current assets	10,303,118	'	9,777,129	'
Property, plant and equipment, net	3,003,849	'	2,980,268	'
Intangible assets	662,404	'	684,290	'
Goodwill	11,583,342	'	11,595,358	'
Deferred tax asset, non-current	119,945	'	118,306	'
Other assets	5,211,198	'	5,234,132	'
Total assets	30,883,856	'	30,389,483	'
Current liabilities:	'	'	'	'
Accounts payable	517,106	'	511,715	'
Accounts payable to related parties	5,126,683	'	4,931,344	'
Accrued expenses and other current liabilities	1,642,610	'	1,786,709	'
Short-term borrowings and other financial liabilities	100,690	'	96,588	'
Short Term Borrowings Due To Related Parties Current Acquisitions	134,314	'	62,342	'
Current portion of long-term debt and capital lease obligations	23,080	'	40,280	'
Income tax payable, current	85,921	'	56,163	'
Deferred tax liability, current	66,021	'	64,539	'
Total current liabilities	7,696,425	'	7,549,680	'
Total long-term debt less current maturities	7,681,126	'	7,478,944	'
Long term borrowings from related parties	6,491	'	6,940	'
Other liabilities	30,366	'	30,399	'
Pension liabilities	142,892	'	171,248	'
Income tax payable, non-current	21,549	'	20,262	'
Deferred tax liability, non-current	759,967	'	768,156	'
Total liabilities	16,338,816	'	16,025,629	'
Noncontrolling interests subject to put provisions	631,940	'	648,251	'
Company shareholders' equity	13,656,823	'	13,465,147	'
Minority interest	256,277	'	250,456	'
Total equity	13,913,100	'	13,715,603	'
Total liabilities and equity	30,883,856	'	30,389,483	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	179,824	304,267	'	'
Other comprehensive income loss derivatives qualifying as hedges before tax	-275	3,033	'	'
Other comprehensive income loss pension and other post retirement benefit plans net unamortized gain loss arising during period before tax	95	61	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	-50,268	-115,710	'	'
Other comprehensive income loss tax	110	-555	'	'
Other comprehensive income (loss), net of tax	-50,338	-113,171	'	'
Total comprehensive income	129,486	191,096	'	'
Comprehensive income attributable to the Company	129,486	191,096	'	'
Combining Adjustment [Member]	'	'	'	'
Consolidated Statements of Income	'	'	'	'
Net revenue	-864,712	-790,202	'	'
Cost of revenues	-845,699	-778,255	'	'
Gross profit	-19,013	-11,947	'	'
Selling, general and administrative	-11,887	25,857	'	'
Research and development	0	-169	'	'
Operating income	-7,126	-37,635	'	'
Other (income) expense:	'	'	'	'
Other, net	373,903	349,039	'	'
Income before income taxes	-381,079	-386,674	'	'
Income tax expense	-95,075	34,015	'	'
Net Income	-286,004	-420,689	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	2,524	2,296	'	'
Less: Net income attributable to noncontrolling interests	41,888	34,584	'	'
Income attributable to the Company	-327,892	-455,273	'	'
Current assets:	'	'	'	'
Cash and cash equivalents	-689	65,410	6,068	1,003
Trade accounts receivable less allowance for doubtful accounts of $403,657 in 2014 and $413,165 in 2013	1,766	'	2,058	'
Accounts receivable from related parties	-9,138,792	'	-8,609,228	'
Inventories	-154,661	'	-137,311	'
Prepaid expenses and other current assets	36,728	'	44,960	'
Deferred tax asset, current	-43,848	'	-43,285	'
Total current assets	-9,299,496	'	-8,736,738	'
Property, plant and equipment, net	-124,790	'	-127,517	'
Intangible assets	-91	'	-81	'
Deferred tax asset, non-current	-109,592	'	-109,279	'
Other assets	-31,122,565	'	-30,599,966	'
Total assets	-40,656,534	'	-39,573,581	'
Current liabilities:	'	'	'	'
Accounts payable to related parties	-9,399,513	'	-8,827,326	'
Accrued expenses and other current liabilities	9,243	'	11,027	'
Income tax payable, current	-5,554	'	'	'
Deferred tax liability, current	-42,646	'	-41,678	'
Total current liabilities	-9,438,470	'	-8,857,977	'
Total long-term debt less current maturities	-3,569,675	'	-3,434,378	'
Long term borrowings from related parties	-5,458,265	'	-5,459,364	'
Other liabilities	23,605	'	19,604	'
Pension liabilities	-953	'	'	'
Income tax payable, non-current	110,736	'	123,538	'
Deferred tax liability, non-current	-25,638	'	-24,766	'
Total liabilities	-18,358,660	'	-17,633,343	'
Company shareholders' equity	-22,297,874	'	-21,940,238	'
Total equity	-22,297,874	'	-21,940,238	'
Total liabilities and equity	-40,656,534	'	-39,573,581	'
Consolidated Statements of Comprehensive Income	'	'	'	'
Net Income	-286,004	-420,689	'	'
Other comprehensive income loss foreign currency transaction and translation adjustment before tax	2,524	2,296	'	'
Other comprehensive income (loss), net of tax	2,524	2,296	'	'
Total comprehensive income	-283,480	-418,393	'	'
Comprehensive income attributable to noncontrolling interests	-41,855	-32,602	'	'
Comprehensive income attributable to the Company	($325,335)	($450,995)	'	'

Supplementary_Cash_Flow_Inform2

Supplementary Cash Flow Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Supplementary cash flow information:	'	'
Cash paid for interest	$164,393	$165,596
Cash paid for income taxes, net of tax refund	83,138	59,708
Cash inflow for income taxes from stock option exercises	545	522
Supplemental disclosures of cash flow information, details for acquisitions:	'	'
Assets acquired	-31,589	-69,485
Liabilities assumed	2,251	3,334
Noncontrolling interest	288	4,527
Notes assumed in connection with acquisition	7,569	3,690
Noncontrolling Interest Subject To Put Provisions	0	6,294
Cash Paid	-21,481	-51,640
Less cash acquired in acquisition	105	2,530
Net cash paid for acquisitions	-21,376	-49,110
CashPaidForInvestments	-112,848	-22,185
Cash Paid For Intangible Assets	-2,933	-919
Cash Paid For Acquisitions And Investments Net Of Cash Acquired And Purchases Of Intangible Assets	($137,157)	($72,214)

Supplemental_Condensed_Combini3

Supplemental Condensed Combining Information (Details 1) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating Activities:	'	'
Net Income	$247,350	$260,083
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	167,167	156,353
Change in deferred taxes, net	-3,459	-22,455
Stock Option Compensation Expense	6,174	6,220
Dividend income from equity method investees	32,399	18,582
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	-62,915	-40,702
Inventories, net	-111,648	-56,173
Prepaid expenses, other current and non-current assets	-26,831	32,079
Accounts payable, accrued expenses and other current and non-current liabilities	-180,308	-99,671
Income tax payable	20,756	62,249
Net cash provided by (used in) operating activities	112,294	315,418
Investing Activities:	'	'
Purchases of property, plant and equipment	-199,631	-147,357
Proceeds from sale of property, plant and equipment	2,480	1,327
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	-137,157	-72,214
Proceeds from divestitures	2,381	1,036
Net cash (used in) provided by investing activities	-331,927	-217,208
Financing Activities:	'	'
Increase (decrease) of accounts receivable securitization program	68,000	-162,000
Proceeds from exercise of stock options	5,807	4,635
Distributions to noncontrolling interests	'	72,619
Contributions from noncontrolling interests	13,402	8,795
Net cash (used in) provided by financing activities	116,211	-246,467
Effect of exchange rate changes on cash and cash equivalents	-5,228	-4,942
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	-108,650	-153,199
Cash and cash equivalents at beginning of period	682,777	688,040
Cash and cash equivalents at end of period	574,127	'
Issuers [Member] | FMC US Finance [Member]	'	'
Operating Activities:	'	'
Net Income	1,103	1,081
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Accounts receivable from/payable to related parties	19,214	-8,547
Accounts payable, accrued expenses and other current and non-current liabilities	-17,938	-7,273
Income tax payable	628	616
Net cash provided by (used in) operating activities	3,007	2,971
Financing Activities:	'	'
Long-term debt and capital lease obligations, net	-3,007	-2,972
Net cash (used in) provided by financing activities	-3,007	-2,972
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	'	-1
Cash and cash equivalents at beginning of period	'	1
Cash and cash equivalents at end of period	0	0
Guarantors [Member] | Total FMC-AG and Co. KGaA [Member]	'	'
Operating Activities:	'	'
Net Income	205,462	225,499
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	-124,293	-117,240
Depreciation and amortization	168	169
Change in deferred taxes, net	-5,141	-14,876
(Gain) loss on sale of fixed assets and investments	'	-12
Write-off of loans from related parties	54,513	'
Stock Option Compensation Expense	6,174	6,220
Dividend income from equity method investees	-43,389	-22,816
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Prepaid expenses, other current and non-current assets	27,932	-19,210
Accounts receivable from/payable to related parties	68,641	76,649
Accounts payable, accrued expenses and other current and non-current liabilities	-1,925	3,603
Income tax payable	8,954	-923
Net cash provided by (used in) operating activities	283,874	29,397
Investing Activities:	'	'
Purchases of property, plant and equipment	'	14
Proceeds from sale of property, plant and equipment	'	17
Disbursements of loans to related parties	-88,773	22,515
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	63,444	23,152
Net cash (used in) provided by investing activities	-152,217	-45,664
Financing Activities:	'	'
Short-term borrowings, net	-60	4,226
Long-term debt and capital lease obligations, net	-136,960	'
Proceeds from exercise of stock options	-5,266	-4,113
Net cash (used in) provided by financing activities	-131,754	8,339
Effect of exchange rate changes on cash and cash equivalents	377	8,461
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	280	533
Cash and cash equivalents at beginning of period	13	78
Cash and cash equivalents at end of period	293	611
Guarantors [Member] | D GmbH [Member]	'	'
Operating Activities:	'	'
Net Income	3,821	-11,711
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	13,209	12,184
Change in deferred taxes, net	1,004	2,705
(Gain) loss on sale of fixed assets and investments	-48	-115
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	10,600	-15,829
Inventories, net	-26,758	-12,488
Prepaid expenses, other current and non-current assets	-28,285	-9,435
Accounts receivable from/payable to related parties	126,606	-52,601
Accounts payable, accrued expenses and other current and non-current liabilities	23,947	19,261
Net cash provided by (used in) operating activities	124,096	37,173
Investing Activities:	'	'
Purchases of property, plant and equipment	28,346	13,577
Proceeds from sale of property, plant and equipment	-128	'
Disbursements of loans to related parties	'	180
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	1,216	1,424
Net cash (used in) provided by investing activities	-29,434	-14,821
Financing Activities:	'	'
Short-term borrowings, net	-93,960	-22,794
Net cash (used in) provided by financing activities	-93,960	-22,794
Effect of exchange rate changes on cash and cash equivalents	6	-2
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	708	-444
Cash and cash equivalents at beginning of period	4,490	501
Cash and cash equivalents at end of period	5,198	57
Guarantors [Member] | FMCH [Member]	'	'
Operating Activities:	'	'
Net Income	143,144	161,636
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	-154,698	-181,689
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Prepaid expenses, other current and non-current assets	-25,230	-6,047
Accounts receivable from/payable to related parties	-1,109	-28,490
Accounts payable, accrued expenses and other current and non-current liabilities	-455	-921
Income tax payable	-7,528	-13,065
Net cash provided by (used in) operating activities	-45,876	-11,596
Investing Activities:	'	'
Disbursements of loans to related parties	-63,712	-83,644
Net cash (used in) provided by investing activities	-63,712	83,644
Financing Activities:	'	'
Long-term debt and capital lease obligations, net	109,588	1,659,914
Capital (decrease) increase	'	1,731,962
Net cash (used in) provided by financing activities	109,588	-72,048
Non Guarantor Subsidiaries [Member]	'	'
Operating Activities:	'	'
Net Income	179,824	304,267
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	162,641	151,774
Change in deferred taxes, net	6,310	-3,914
(Gain) loss on sale of fixed assets and investments	854	455
Dividend income from equity method investees	10,990	4,234
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	-73,804	-24,873
Inventories, net	-104,322	-59,019
Prepaid expenses, other current and non-current assets	5,543	66,903
Accounts receivable from/payable to related parties	-214,030	80,161
Accounts payable, accrued expenses and other current and non-current liabilities	-183,359	-115,523
Income tax payable	36,852	50,431
Net cash provided by (used in) operating activities	-194,481	286,106
Investing Activities:	'	'
Purchases of property, plant and equipment	179,465	139,502
Proceeds from sale of property, plant and equipment	-2,352	1,130
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	136,985	69,095
Proceeds from divestitures	-2,381	-63,452
Net cash (used in) provided by investing activities	-311,717	-270,919
Financing Activities:	'	'
Short-term borrowings, net	171,121	25,607
Long-term debt and capital lease obligations, net	186,922	-1,750,388
Increase (decrease) of accounts receivable securitization program	68,000	162,000
Proceeds from exercise of stock options	-541	-522
Capital (decrease) increase	-21,099	-1,730,603
Distributions to noncontrolling interests	52,157	72,619
Contributions from noncontrolling interests	13,402	8,795
Net cash (used in) provided by financing activities	408,928	-219,480
Effect of exchange rate changes on cash and cash equivalents	-5,611	-13,401
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	-102,881	-217,694
Cash and cash equivalents at beginning of period	672,206	686,457
Cash and cash equivalents at end of period	569,325	468,763
Combining Adjustment [Member]	'	'
Operating Activities:	'	'
Net Income	-286,004	-420,689
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Income Loss From Equity Method Investments Net Of Dividends Or Distributions	278,991	298,929
Depreciation and amortization	-8,851	-7,774
Change in deferred taxes, net	-5,632	-6,370
Write-off of loans from related parties	-54,513	'
Changes in assets and liabilities, net of amounts from businesses acquired:	'	'
Trade accounts receivable, net	289	'
Inventories, net	19,432	15,334
Prepaid expenses, other current and non-current assets	-6,791	-132
Accounts receivable from/payable to related parties	23,481	-65,697
Accounts payable, accrued expenses and other current and non-current liabilities	-578	1,182
Income tax payable	-18,150	25,190
Net cash provided by (used in) operating activities	-58,326	-28,633
Investing Activities:	'	'
Purchases of property, plant and equipment	-8,180	-5,736
Disbursements of loans to related parties	152,485	61,129
Acquisitions and investments, net of cash acquired, and net purchases of intangible assets	-64,488	-21,457
Proceeds from divestitures	'	64,488
Net cash (used in) provided by investing activities	225,153	30,552
Financing Activities:	'	'
Long-term debt and capital lease obligations, net	-152,485	61,129
Capital (decrease) increase	21,099	-1,359
Net cash (used in) provided by financing activities	-173,584	62,488
Cash and Cash Equivalents:	'	'
(decrease) in cash and cash equivalents	-6,757	64,407
Cash and cash equivalents at beginning of period	6,068	1,003
Cash and cash equivalents at end of period	($689)	$65,410